Scaling without slippage
Revenue up 54.0% YoY while gross margin expanded +259.9pp TTM to 340.1%
Frame pre-revenue biotech around cash runway, burn, and pipeline optionality instead of near-term profitability.
Pre-revenue biotech is not a margin story. It is a survival-and-optionality story shaped by cash runway, burn rate, R&D intensity, financing risk, and the value of future pipeline outcomes. The StatsAlpha(TM) biotech framework is designed to make that reality visible through runway-focused money flow, selective peer context, and a deliberately cautious analytical stance. It is for informational purposes only, not investment advice.
A quick read on where this framework looks strongest today.
Top slices selected from the strongest data already available for this industry.
Top 5 companies by current framework view
Recurring storylines, tone distribution, and representative beats pulled from active companies inside this setup.
Revenue up 54.0% YoY while gross margin expanded +259.9pp TTM to 340.1%
Revenue up 232.6% YoY while gross margin expanded +20.7pp TTM to 100.0%
Revenue up 30.2% YoY while gross margin expanded +26.1pp TTM to 97.9%
For informational purposes only. Not investment advice.
Metrics that recur most often across stronger operators in this framework.
Pre-Revenue Biotech
This framework softens or disables Profitability in the Trade-Off Ledger lens.
Each axis sets a minimum evidence threshold. Higher coverage means the framework needs more supporting signals before the lens is treated as dependable.
Coverage thresholds and enabled metrics across the core trade-off axes.
Median and interquartile range across 1022 companies in this framework.
Interquartile ranges show where the middle half of companies cluster, with the median pin marking the center of gravity for each pillar.
Scan the full company universe mapped into the Biotech / Pre-Revenue framework using live search across company name, ticker, and industry.
| Company | Market Cap | Score | Price | Strongest Pillar |
|---|---|---|---|---|
|
Biotechnology
|
108.54B
|
71.6
Composite
|
$425.00
|
Profitability
89.8
|
|
Biotechnology
|
75.59B
|
69.3
Composite
|
$709.10
|
Profitability
90.3
|
|
ARGX
argenx SE
Biotechnology
|
48.72B
|
67.8
Composite
|
$787.31
|
Profitability
85.8
|
|
Biotechnology
|
39.51B
|
70.4
Composite
|
$295.91
|
Profitability
86.8
|
|
ONC
BeiGene, Ltd.
Biotechnology
|
34.82B
|
73.3
Composite
|
$317.00
|
Profitability
86.3
|
|
Biotechnology
|
32.12B
|
42.8
Composite
|
$142.51
|
Efficiency
59.0
|
|
INSM
Insmed Incorporated
Biotechnology
|
29.55B
|
46.2
Composite
|
$105.00
|
Profitability
53.4
|
|
RPRX
Royalty Pharma plc
Biotechnology
|
29.26B
|
72.8
Composite
|
$50.20
|
Profitability
83.5
|
|
Biotechnology
|
25.33B
|
69.5
Composite
|
$569.18
|
Profitability
89.1
|
|
BNTX
BioNTech SE
Biotechnology
|
23.52B
|
62.5
Composite
|
$93.02
|
Profitability
85.9
|
|
Biotechnology
|
20.63B
|
49.2
Composite
|
$28.28
|
Health
66.4
|
|
INCY
Incyte Corporation
Biotechnology
|
19.53B
|
72.8
Composite
|
$97.77
|
Profitability
91.0
|
|
MRNA
Moderna, Inc.
Biotechnology
|
19.26B
|
47.0
Composite
|
$48.54
|
Profitability
63.9
|
|
GMAB
Genmab A/S
Biotechnology
|
17.92B
|
72.4
Composite
|
$27.06
|
Profitability
88.2
|
|
ASND
Ascendis Pharma A/S
Biotechnology
|
14.57B
|
50.6
Composite
|
$246.14
|
Profitability
64.2
|
|
Biotechnology
|
14.34B
|
72.5
Composite
|
$228.57
|
Profitability
81.8
|
|
Biotechnology
|
13.31B
|
46.6
Composite
|
$17.15
|
Profitability
56.2
|
|
Biotechnology
|
13.21B
|
45.4
Composite
|
$67.45
|
Profitability
61.4
|
|
Biotechnology
|
12.47B
|
53.7
Composite
|
$76.02
|
Health
66.4
|
|
Biotechnology
|
12.33B
|
54.2
Composite
|
$534.86
|
Profitability
68.4
|
|
EXEL
Exelixis, Inc.
Biotechnology
|
11.62B
|
66.9
Composite
|
$46.21
|
Profitability
91.3
|
|
Biotechnology
|
11.33B
|
55.2
Composite
|
$220.22
|
Health
70.1
|
|
Biotechnology
|
10.92B
|
69.9
Composite
|
$77.95
|
Profitability
84.7
|
|
Biotechnology
|
10.46B
|
66.8
Composite
|
$54.12
|
Profitability
84.8
|
|
ABVX
Abivax SA
Biotechnology
|
10.26B
|
40.0
Composite
|
$124.65
|
Health
55.1
|
|
Biotechnology
|
9.42B
|
37.8
Composite
|
$333.28
|
Efficiency
50.0
|
|
Biotechnology
|
9.24B
|
40.6
Composite
|
$74.29
|
Efficiency
51.8
|
|
Biotechnology
|
8.75B
|
70.9
Composite
|
$296.70
|
Profitability
91.0
|
|
IBRX
ImmunityBio, Inc.
Biotechnology
|
8.65B
|
46.8
Composite
|
$7.76
|
Growth
64.0
|
|
NUVL
Nuvalent, Inc.
Biotechnology
|
8.23B
|
54.1
Composite
|
$102.40
|
Profitability
73.9
|
|
Biotechnology
|
7.69B
|
71.3
Composite
|
$65.19
|
Profitability
84.3
|
|
PCVX
Vaxcyte, Inc.
Biotechnology
|
7.43B
|
48.1
Composite
|
$51.48
|
Health
55.6
|
|
TECH
Bio-Techne Corp
Biotechnology
|
7.42B
|
71.5
Composite
|
$50.91
|
Profitability
84.7
|
|
Biotechnology
|
7.10B
|
48.9
Composite
|
$84.63
|
Profitability
61.2
|
|
ACLX
Arcellx, Inc.
Biotechnology
|
6.75B
|
51.7
Composite
|
$115.07
|
Profitability
64.5
|
|
CELC
Celcuity Inc.
Biotechnology
|
6.74B
|
42.5
Composite
|
$130.71
|
Health
61.0
|
|
Biotechnology
|
6.71B
|
67.6
Composite
|
$102.93
|
Profitability
82.9
|
|
Biotechnology
|
6.70B
|
64.1
Composite
|
$43.02
|
Profitability
87.6
|
|
Biotechnology
|
6.69B
|
52.0
Composite
|
$98.85
|
Profitability
68.8
|
|
Biotechnology
|
6.59B
|
50.5
Composite
|
$96.23
|
Health
59.6
|
|
Biotechnology
|
6.35B
|
58.6
Composite
|
$73.10
|
Profitability
64.1
|
|
Biotechnology
|
6.32B
|
52.5
Composite
|
$81.81
|
Health
59.1
|
|
BLTE
Belite Bio, Inc
Biotechnology
|
6.15B
|
53.2
Composite
|
$156.00
|
Profitability
71.9
|
|
Biotechnology
|
6.13B
|
51.3
Composite
|
$39.61
|
Profitability
66.8
|
|
Biotechnology
|
6.11B
|
53.8
Composite
|
$52.95
|
Health
59.7
|
|
CGON
CG Oncology, Inc.
Biotechnology
|
6.09B
|
48.7
Composite
|
$69.18
|
Valuation
56.7
|
|
Biotechnology
|
5.95B
|
49.5
Composite
|
$34.79
|
Valuation
60.6
|
|
Biotechnology
|
5.62B
|
50.7
Composite
|
$46.45
|
Health
58.2
|
|
IMVT
Immunovant, Inc.
Biotechnology
|
5.54B
|
53.5
Composite
|
$27.22
|
Health
67.7
|
|
Biotechnology
|
5.51B
|
60.7
Composite
|
$64.49
|
Profitability
81.8
|
|
Biotechnology
|
5.48B
|
70.4
Composite
|
$51.05
|
Profitability
90.1
|
|
Biotechnology
|
5.28B
|
63.4
Composite
|
$28.57
|
Profitability
74.1
|
|
Biotechnology
|
5.26B
|
66.8
Composite
|
$41.01
|
Profitability
83.8
|
|
Biotechnology
|
5.06B
|
42.0
Composite
|
$52.42
|
Health
62.2
|
|
Biotechnology
|
4.87B
|
47.4
Composite
|
$56.00
|
Profitability
57.6
|
|
Biotechnology
|
4.67B
|
50.5
Composite
|
$85.47
|
Health
67.6
|
|
Biotechnology
|
4.64B
|
72.9
Composite
|
$210.33
|
Profitability
88.5
|
|
Biotechnology
|
4.55B
|
41.9
Composite
|
$43.49
|
Efficiency
57.1
|
|
Biotechnology
|
4.55B
|
61.9
Composite
|
$14.49
|
Profitability
75.2
|
|
ORKA
ARCA biopharma Inc
Biotechnology
|
4.18B
|
58.9
Composite
|
$64.07
|
Profitability
69.1
|
|
Biotechnology
|
4.16B
|
65.6
Composite
|
$42.66
|
Profitability
81.7
|
|
Biotechnology
|
3.98B
|
51.5
Composite
|
$35.58
|
Health
59.1
|
|
Biotechnology
|
3.85B
|
67.8
Composite
|
$22.56
|
Profitability
89.0
|
|
Biotechnology
|
3.75B
|
35.4
Composite
|
$31.58
|
Efficiency
57.6
|
|
LQDA
Liquidia Corporation
Biotechnology
|
3.75B
|
63.0
Composite
|
$42.28
|
Profitability
78.6
|
|
Biotechnology
|
3.73B
|
67.2
Composite
|
$31.17
|
Profitability
89.3
|
|
Biotechnology
|
3.71B
|
67.7
Composite
|
$10.66
|
Profitability
81.0
|
|
Biotechnology
|
3.56B
|
51.2
Composite
|
$34.85
|
Profitability
58.2
|
|
ERAS
Erasca, Inc.
Biotechnology
|
3.39B
|
56.5
Composite
|
$10.40
|
Profitability
65.0
|
|
Biotechnology
|
3.39B
|
67.8
Composite
|
$23.48
|
Profitability
88.5
|
|
Biotechnology
|
3.27B
|
50.3
Composite
|
$24.78
|
Profitability
56.2
|
|
ALMS
Alumis Inc.
Biotechnology
|
3.24B
|
40.4
Composite
|
$25.50
|
Growth
53.8
|
|
Biotechnology
|
3.24B
|
54.9
Composite
|
$31.47
|
Profitability
68.5
|
|
Biotechnology
|
3.13B
|
49.6
Composite
|
$19.71
|
Profitability
63.8
|
|
Biotechnology
|
2.90B
|
52.8
Composite
|
$17.54
|
Valuation
63.2
|
|
Biotechnology
|
2.78B
|
52.5
Composite
|
$39.15
|
Health
64.3
|
|
Biotechnology
|
2.75B
|
61.1
Composite
|
$63.96
|
Profitability
75.6
|
|
Biotechnology
|
2.73B
|
69.5
Composite
|
$52.95
|
Profitability
88.5
|
|
Biotechnology
|
2.71B
|
35.5
Composite
|
$43.68
|
Valuation
48.4
|
|
Biotechnology
|
2.62B
|
45.6
Composite
|
$35.88
|
Health
51.0
|
|
IRON
Disc Medicine, Inc.
Biotechnology
|
2.62B
|
55.2
Composite
|
$67.53
|
Profitability
66.5
|
|
Biotechnology
|
2.58B
|
61.9
Composite
|
$20.66
|
Profitability
80.0
|
|
Biotechnology
|
2.57B
|
43.7
Composite
|
$26.13
|
Efficiency
55.0
|
|
IMNM
Immunome, Inc.
Biotechnology
|
2.51B
|
50.7
Composite
|
$22.19
|
Profitability
54.2
|
|
Biotechnology
|
2.48B
|
58.9
Composite
|
$28.24
|
Profitability
77.7
|
|
Biotechnology
|
2.45B
|
53.3
Composite
|
$40.29
|
Growth
65.8
|
|
NKTR
Nektar Therapeutics
Biotechnology
|
2.44B
|
46.9
Composite
|
$83.37
|
Health
57.6
|
|
Biotechnology
|
2.42B
|
53.3
Composite
|
$29.35
|
Growth
74.1
|
|
ADMA
ADMA Biologics Inc
Biotechnology
|
2.40B
|
62.8
Composite
|
$8.47
|
Profitability
86.5
|
|
Biotechnology
|
2.40B
|
47.9
Composite
|
$12.51
|
Health
52.6
|
|
Biotechnology
|
2.35B
|
58.1
Composite
|
$14.69
|
Profitability
72.8
|
|
ZLAB
Zai Lab Limited
Biotechnology
|
2.32B
|
54.5
Composite
|
$19.77
|
Profitability
67.3
|
|
Biotechnology
|
2.26B
|
65.9
Composite
|
$8.90
|
Profitability
82.0
|
|
Biotechnology
|
2.22B
|
55.3
Composite
|
$21.53
|
Profitability
67.9
|
|
Biotechnology
|
2.22B
|
42.7
Composite
|
$33.32
|
Health
55.5
|
|
Biotechnology
|
2.20B
|
55.3
Composite
|
$20.80
|
Profitability
73.5
|
|
Biotechnology
|
2.16B
|
67.2
Composite
|
$15.14
|
Profitability
88.0
|
|
Biotechnology
|
2.12B
|
49.8
Composite
|
$9.68
|
Health
66.2
|
|
Biotechnology
|
2.07B
|
53.5
Composite
|
$32.79
|
Profitability
65.9
|
|
Biotechnology
|
2.06B
|
70.5
Composite
|
$21.70
|
Profitability
84.6
|
|
ZYME
Zymeworks Inc.
Biotechnology
|
2.04B
|
56.7
Composite
|
$26.60
|
Profitability
77.2
|
|
Biotechnology
|
2.02B
|
47.6
Composite
|
$14.05
|
Growth
74.8
|
|
Biotechnology
|
2.01B
|
48.3
Composite
|
$32.90
|
Valuation
57.1
|
|
NBTX
Nanobiotix S.A.
Biotechnology
|
1.98B
|
50.5
Composite
|
$42.61
|
Profitability
69.3
|
|
Biotechnology
|
1.98B
|
49.2
Composite
|
$33.94
|
Profitability
61.5
|
|
PHVS
Pharvaris N.V.
Biotechnology
|
1.97B
|
49.0
Composite
|
$29.68
|
Profitability
56.2
|
|
Biotechnology
|
1.95B
|
50.5
Composite
|
$43.31
|
Profitability
66.6
|
|
ANAB
AnaptysBio, Inc.
Biotechnology
|
1.93B
|
54.9
Composite
|
$66.96
|
Profitability
66.9
|
|
Biotechnology
|
1.92B
|
52.2
Composite
|
$6.67
|
Profitability
57.3
|
|
MESO
Mesoblast Limited
Biotechnology
|
1.91B
|
49.3
Composite
|
$14.80
|
Health
58.9
|
|
VCEL
Vericel Corporation
Biotechnology
|
1.87B
|
69.2
Composite
|
$35.13
|
Profitability
85.2
|
|
Biotechnology
|
1.86B
|
48.3
Composite
|
$113.26
|
Growth
56.2
|
|
GLPG
Galapagos NV
Biotechnology
|
1.86B
|
59.5
Composite
|
$27.73
|
Profitability
84.0
|
|
Biotechnology
|
1.82B
|
45.2
Composite
|
$20.54
|
Health
53.7
|
|
Biotechnology
|
1.82B
|
39.6
Composite
|
$124.52
|
Health
54.2
|
|
Biotechnology
|
1.82B
|
72.5
Composite
|
$31.42
|
Profitability
86.9
|
|
Biotechnology
|
1.81B
|
46.4
Composite
|
$3.27
|
Valuation
55.7
|
|
Biotechnology
|
1.81B
|
49.7
Composite
|
$17.00
|
Health
59.7
|
|
Biotechnology
|
1.79B
|
56.9
Composite
|
$58.01
|
Profitability
67.8
|
|
Biotechnology
|
1.78B
|
54.8
Composite
|
$15.20
|
Profitability
63.6
|
|
Biotechnology
|
1.77B
|
54.5
Composite
|
$39.93
|
Profitability
67.9
|
|
Biotechnology
|
1.75B
|
45.9
Composite
|
$31.09
|
Growth
61.5
|
|
Biotechnology
|
1.75B
|
39.9
Composite
|
$18.09
|
Valuation
63.6
|
|
ARDX
Ardelyx, Inc.
Biotechnology
|
1.72B
|
59.0
Composite
|
$6.98
|
Profitability
70.0
|
|
Biotechnology
|
1.68B
|
48.5
Composite
|
$16.28
|
Health
55.9
|
|
NUVB
Nuvation Bio Inc.
Biotechnology
|
1.67B
|
53.6
Composite
|
$4.81
|
Profitability
63.7
|
|
INVA
Innoviva, Inc.
Biotechnology
|
1.67B
|
74.5
Composite
|
$22.80
|
Profitability
85.7
|
|
Biotechnology
|
1.66B
|
39.7
Composite
|
$9.27
|
Profitability
48.6
|
|
Biotechnology
|
1.64B
|
45.6
Composite
|
$27.53
|
Efficiency
55.3
|
|
Biotechnology
|
1.64B
|
49.8
Composite
|
$13.71
|
Profitability
61.2
|
|
Biotechnology
|
1.63B
|
59.5
Composite
|
$19.81
|
Profitability
70.0
|
|
Biotechnology
|
1.56B
|
50.9
Composite
|
$30.62
|
Profitability
73.2
|
|
Biotechnology
|
1.56B
|
48.7
Composite
|
$23.09
|
Profitability
65.8
|
|
PGEN
Precigen, Inc.
Biotechnology
|
1.56B
|
35.4
Composite
|
$4.15
|
Health
52.1
|
|
Biotechnology
|
1.53B
|
44.6
Composite
|
$4.01
|
Growth
59.1
|
|
Biotechnology
|
1.53B
|
60.6
Composite
|
$34.71
|
Efficiency
68.0
|
|
QURE
uniQure N.V.
Biotechnology
|
1.52B
|
46.1
Composite
|
$24.15
|
Health
61.4
|
|
NVAX
Novavax, Inc.
Biotechnology
|
1.52B
|
55.1
Composite
|
$9.23
|
Profitability
74.7
|
|
BHVN
Biohaven Ltd.
Biotechnology
|
1.51B
|
40.5
Composite
|
$9.74
|
Profitability
46.7
|
|
IMTX
Immatics N.V.
Biotechnology
|
1.49B
|
51.5
Composite
|
$11.14
|
Efficiency
60.9
|
|
GLTO
Galecto, Inc.
Biotechnology
|
1.49B
|
49.1
Composite
|
$24.99
|
Valuation
62.5
|
|
Biotechnology
|
1.47B
|
51.7
Composite
|
$15.57
|
Profitability
58.9
|
|
Biotechnology
|
1.46B
|
57.9
Composite
|
$25.47
|
Profitability
74.4
|
|
Biotechnology
|
1.46B
|
50.3
Composite
|
$3.55
|
Efficiency
60.1
|
|
Biotechnology
|
1.46B
|
53.4
Composite
|
$4.82
|
Profitability
62.6
|
|
Biotechnology
|
1.39B
|
49.2
Composite
|
$7.24
|
Health
61.7
|
|
GHRS
GH Research PLC
Biotechnology
|
1.39B
|
50.8
Composite
|
$21.01
|
Profitability
73.9
|
|
Biotechnology
|
1.37B
|
62.5
Composite
|
$28.85
|
Profitability
72.9
|
|
Biotechnology
|
1.37B
|
45.7
Composite
|
$26.72
|
Health
60.5
|
|
Biotechnology
|
1.32B
|
51.0
Composite
|
$15.13
|
Growth
54.7
|
|
Biotechnology
|
1.30B
|
50.9
Composite
|
$14.59
|
Growth
72.5
|
|
URGN
UroGen Pharma Ltd.
Biotechnology
|
1.28B
|
47.4
Composite
|
$26.59
|
Profitability
57.6
|
|
Biotechnology
|
1.23B
|
37.7
Composite
|
$17.20
|
Valuation
50.5
|
|
Biotechnology
|
1.18B
|
41.1
Composite
|
$19.99
|
Valuation
55.1
|
|
Biotechnology
|
1.15B
|
52.8
Composite
|
$19.27
|
Profitability
60.3
|
|
Biotechnology
|
1.12B
|
36.7
Composite
|
$13.41
|
Efficiency
55.0
|
|
Biotechnology
|
1.10B
|
31.2
Composite
|
$5.35
|
Health
48.2
|
|
Biotechnology
|
1.10B
|
64.6
Composite
|
$6.63
|
Profitability
80.2
|
|
MNKD
MannKind Corporation
Biotechnology
|
1.10B
|
63.9
Composite
|
$3.55
|
Profitability
83.5
|
|
SVRA
Savara, Inc.
Biotechnology
|
1.08B
|
42.4
Composite
|
$5.16
|
Health
50.5
|
|
SEPN
Septerna, Inc.
Biotechnology
|
1.08B
|
70.0
Composite
|
$23.98
|
Profitability
86.7
|
|
OMER
Omeros Corporation
Biotechnology
|
1.07B
|
38.7
Composite
|
$14.64
|
Growth
52.9
|
|
Biotechnology
|
1.01B
|
53.7
Composite
|
$12.23
|
Profitability
69.6
|
|
Biotechnology
|
1.00B
|
49.2
Composite
|
$14.00
|
Valuation
58.7
|
|
Biotechnology
|
971.25M
|
52.7
Composite
|
$3.50
|
Profitability
60.6
|
|
XNCR
Xencor, Inc.
Biotechnology
|
954.10M
|
56.7
Composite
|
$12.31
|
Profitability
69.8
|
|
GERN
Geron Corporation
Biotechnology
|
936.60M
|
55.8
Composite
|
$1.46
|
Profitability
75.4
|
|
Biotechnology
|
924.90M
|
51.4
Composite
|
$4.93
|
Growth
71.0
|
|
Biotechnology
|
921.48M
|
55.1
Composite
|
$9.00
|
Profitability
63.7
|
|
Biotechnology
|
921.16M
|
55.4
Composite
|
$14.72
|
Profitability
64.7
|
|
Biotechnology
|
911.99M
|
54.1
Composite
|
$8.81
|
Valuation
64.5
|
|
ANNX
Annexon, Inc.
Biotechnology
|
897.04M
|
49.9
Composite
|
$5.52
|
Health
59.7
|
|
Biotechnology
|
895.95M
|
33.0
Composite
|
$9.68
|
Efficiency
52.9
|
|
ABSI
Absci Corporation
Biotechnology
|
893.82M
|
45.9
Composite
|
$5.75
|
Growth
58.6
|
|
Biotechnology
|
886.38M
|
59.0
Composite
|
$14.54
|
Profitability
76.0
|
|
Biotechnology
|
880.64M
|
53.3
Composite
|
$14.10
|
Profitability
59.9
|
|
Biotechnology
|
874.60M
|
52.1
Composite
|
$88.81
|
Profitability
76.9
|
|
Biotechnology
|
872.30M
|
61.9
Composite
|
$17.02
|
Profitability
83.3
|
|
Biotechnology
|
864.00M
|
51.1
Composite
|
$4.35
|
Profitability
63.5
|
|
Biotechnology
|
861.55M
|
44.2
Composite
|
$16.08
|
Profitability
56.3
|
|
PHAR
Pharming Group N.V.
Biotechnology
|
860.79M
|
67.0
Composite
|
$12.00
|
Profitability
83.6
|
|
KURA
Kura Oncology, Inc.
Biotechnology
|
844.40M
|
51.1
Composite
|
$9.32
|
Profitability
58.3
|
|
Biotechnology
|
843.72M
|
48.4
Composite
|
$24.07
|
Valuation
61.9
|
|
Biotechnology
|
824.40M
|
50.6
Composite
|
$7.43
|
Valuation
69.0
|
|
Biotechnology
|
794.59M
|
45.6
Composite
|
$2.31
|
Valuation
58.2
|
|
Biotechnology
|
784.50M
|
37.9
Composite
|
$13.41
|
Growth
45.5
|
|
Biotechnology
|
779.83M
|
73.1
Composite
|
$7.07
|
Profitability
89.2
|
|
Biotechnology
|
708.40M
|
46.0
Composite
|
$7.07
|
Profitability
59.1
|
|
Shell Companies
|
705.82M
|
46.2
Composite
|
$11.41
|
Profitability
62.5
|
|
Biotechnology
|
685.93M
|
40.1
Composite
|
$11.65
|
Efficiency
46.6
|
|
Shell Companies
|
681.41M
|
54.6
Composite
|
$13.50
|
Profitability
59.3
|
|
Biotechnology
|
680.70M
|
51.1
Composite
|
$4.00
|
Profitability
73.2
|
|
Biotechnology
|
677.90M
|
61.4
Composite
|
$1.60
|
Profitability
72.5
|
|
Biotechnology
|
667.99M
|
48.5
Composite
|
$7.85
|
Profitability
58.7
|
|
Biotechnology
|
659.90M
|
39.5
Composite
|
$39.83
|
Profitability
51.5
|
|
ARVN
Arvinas, Inc.
Biotechnology
|
651.76M
|
54.9
Composite
|
$10.19
|
Profitability
69.2
|
|
Biotechnology
|
650.30M
|
64.4
Composite
|
$11.00
|
Profitability
82.4
|
|
Biotechnology
|
649.16M
|
46.2
Composite
|
$26.17
|
Health
57.6
|
|
CRMD
CorMedix Inc.
Biotechnology
|
636.40M
|
69.2
Composite
|
$7.92
|
Profitability
89.4
|
|
ALT
Altimmune, Inc.
Biotechnology
|
633.09M
|
47.9
Composite
|
$3.26
|
Growth
62.7
|
|
CABA
Cabaletta Bio, Inc.
Biotechnology
|
608.18M
|
46.5
Composite
|
$4.00
|
Health
53.2
|
|
PRME
Prime Medicine, Inc.
Biotechnology
|
604.06M
|
45.9
Composite
|
$3.12
|
Growth
66.2
|
|
Biotechnology
|
601.90M
|
46.7
Composite
|
$10.52
|
Health
54.5
|
|
ENGN
enGene Holdings Inc.
Biotechnology
|
592.86M
|
39.9
Composite
|
$1.72
|
Valuation
53.7
|
|
PROK
ProKidney Corp.
Biotechnology
|
591.80M
|
48.0
Composite
|
$1.88
|
Efficiency
70.8
|
|
Biotechnology
|
586.73M
|
41.5
Composite
|
$10.32
|
Profitability
55.1
|
|
Biotechnology
|
585.68M
|
47.3
Composite
|
$6.85
|
Profitability
54.4
|
|
CLYM
Climb Bio, Inc.
Biotechnology
|
583.73M
|
57.1
Composite
|
$11.91
|
Profitability
72.3
|
|
Biotechnology
|
581.13M
|
50.1
Composite
|
$3.94
|
Health
66.5
|
|
Biotechnology
|
573.22M
|
46.9
Composite
|
$9.30
|
Profitability
57.5
|
|
Biotechnology
|
558.87M
|
61.2
Composite
|
$7.79
|
Profitability
68.9
|
|
MDXG
MiMedx Group, Inc
Biotechnology
|
549.60M
|
72.2
Composite
|
$3.69
|
Profitability
88.1
|
|
Biotechnology
|
548.00M
|
39.1
Composite
|
$13.70
|
Health
56.3
|
|
Biotechnology
|
547.08M
|
43.8
Composite
|
$9.54
|
Valuation
59.5
|
|
VALN
Valneva SE
Biotechnology
|
546.89M
|
56.3
Composite
|
$5.56
|
Profitability
69.3
|
|
Biotechnology
|
546.23M
|
59.5
Composite
|
$14.63
|
Profitability
79.2
|
|
RGNX
REGENXBIO Inc.
Biotechnology
|
537.80M
|
49.0
Composite
|
$10.42
|
Health
62.0
|
|
VSTM
Verastem, Inc.
Biotechnology
|
527.90M
|
35.5
Composite
|
$5.66
|
Valuation
40.8
|
|
Biotechnology
|
526.44M
|
51.8
Composite
|
$8.20
|
Profitability
57.7
|
|
Biotechnology
|
519.09M
|
43.7
Composite
|
$9.93
|
Valuation
60.8
|
|
Biotechnology
|
506.46M
|
48.1
Composite
|
$26.87
|
Valuation
55.5
|
|
STTK
Shattuck Labs, Inc.
Biotechnology
|
504.89M
|
55.3
Composite
|
$6.26
|
Profitability
63.0
|
|
NGNE
Neurogene Inc.
Biotechnology
|
504.86M
|
47.0
Composite
|
$31.26
|
Efficiency
59.2
|
|
Biotechnology
|
500.12M
|
50.5
Composite
|
$8.98
|
Efficiency
55.0
|
|
Biotechnology
|
497.50M
|
56.7
Composite
|
$30.93
|
Profitability
74.8
|
|
Biotechnology
|
497.00M
|
40.7
Composite
|
$22.87
|
Efficiency
55.4
|
|
Biotechnology
|
495.30M
|
63.0
Composite
|
$41.29
|
Profitability
81.2
|
|
OCGN
Ocugen, Inc.
Biotechnology
|
487.46M
|
48.3
Composite
|
$1.44
|
Health
65.8
|
|
Biotechnology
|
486.67M
|
50.5
Composite
|
$5.15
|
Growth
55.4
|
|
Biotechnology
|
486.48M
|
45.4
Composite
|
$20.85
|
Valuation
60.6
|
|
Biotechnology
|
485.50M
|
67.8
Composite
|
$26.24
|
Profitability
87.2
|
|
ADCT
ADC Therapeutics SA
Biotechnology
|
476.97M
|
47.0
Composite
|
$3.75
|
Profitability
63.6
|
|
Biotechnology
|
473.76M
|
53.2
Composite
|
$6.88
|
Profitability
67.8
|
|
Biotechnology
|
471.78M
|
56.2
Composite
|
$7.64
|
Profitability
68.4
|
|
Shell Companies
|
471.15M
|
60.0
Composite
|
$11.35
|
Valuation
77.8
|
|
ZURA
Zura Bio Limited
Biotechnology
|
463.97M
|
53.1
Composite
|
$4.54
|
Profitability
60.8
|
|
Biotechnology
|
461.56M
|
47.1
Composite
|
$6.23
|
Efficiency
67.6
|
|
Biotechnology
|
452.44M
|
52.1
Composite
|
$1.61
|
Profitability
55.4
|
|
Biotechnology
|
452.15M
|
57.2
Composite
|
$5.54
|
Profitability
69.1
|
|
Biotechnology
|
442.30M
|
58.6
Composite
|
$15.09
|
Profitability
74.4
|
|
Biotechnology
|
439.80M
|
42.8
Composite
|
$6.39
|
Health
56.2
|
|
Biotechnology
|
430.58M
|
49.8
Composite
|
$12.14
|
Growth
66.5
|
|
Biotechnology
|
425.66M
|
44.3
Composite
|
$1.94
|
Valuation
54.9
|
|
PRTC
PureTech Health plc
Biotechnology
|
425.06M
|
47.0
Composite
|
$16.97
|
Growth
55.1
|
|
Biotechnology
|
422.03M
|
51.2
Composite
|
$2.31
|
Profitability
65.0
|
|
Biotechnology
|
419.10M
|
44.4
Composite
|
$3.67
|
Profitability
51.1
|
|
Biotechnology
|
417.79M
|
58.5
Composite
|
$62.43
|
Growth
82.1
|
|
Biotechnology
|
415.53M
|
46.9
Composite
|
$4.00
|
Health
62.6
|
|
Shell Companies
|
413.65M
|
46.8
Composite
|
$13.00
|
Profitability
62.1
|
|
IVVD
Invivyd, Inc.
Biotechnology
|
412.89M
|
61.1
Composite
|
$1.43
|
Profitability
71.6
|
|
Biotechnology
|
398.23M
|
44.4
Composite
|
$4.29
|
Health
60.8
|
|
Shell Companies
|
396.32M
|
54.1
Composite
|
$10.80
|
Profitability
76.9
|
|
Biotechnology
|
393.13M
|
46.5
Composite
|
$31.04
|
Profitability
52.9
|
|
SRZN
Surrozen, Inc.
Biotechnology
|
392.04M
|
33.0
Composite
|
$30.75
|
Valuation
39.3
|
|
Shell Companies
|
389.56M
|
56.0
Composite
|
$10.80
|
Profitability
77.7
|
|
Shell Companies
|
389.38M
|
42.9
Composite
|
$10.80
|
Efficiency
66.7
|
|
Shell Companies
|
388.12M
|
64.7
Composite
|
$10.80
|
Profitability
82.6
|
|
Biotechnology
|
379.00M
|
66.1
Composite
|
$7.26
|
Profitability
85.0
|
|
Biotechnology
|
375.58M
|
45.5
Composite
|
$5.36
|
Valuation
52.3
|
|
Biotechnology
|
366.60M
|
44.6
Composite
|
$2.73
|
Growth
51.8
|
|
Biotechnology
|
365.99M
|
49.4
Composite
|
$2.88
|
Profitability
60.4
|
|
Shell Companies
|
359.22M
|
56.7
Composite
|
$18.65
|
Profitability
84.5
|
|
Biotechnology
|
356.20M
|
46.1
Composite
|
$1.37
|
Profitability
55.0
|
|
Biotechnology
|
351.90M
|
52.8
Composite
|
$6.53
|
Profitability
71.2
|
|
Biotechnology
|
348.00M
|
39.4
Composite
|
$0.22
|
Efficiency
52.3
|
|
Biotechnology
|
347.64M
|
47.3
Composite
|
$6.95
|
Growth
58.9
|
|
Shell Companies
|
345.25M
|
52.6
Composite
|
$11.00
|
Profitability
85.3
|
|
Biotechnology
|
342.61M
|
44.9
Composite
|
$1.99
|
Growth
63.4
|
|
Biotechnology
|
340.87M
|
48.6
Composite
|
$4.89
|
Profitability
63.8
|
|
Biotechnology
|
335.78M
|
62.1
Composite
|
$5.22
|
Profitability
73.0
|
|
Biotechnology
|
335.76M
|
33.0
Composite
|
$9.15
|
Valuation
42.7
|
|
PALI
Palisade Bio, Inc.
Biotechnology
|
333.17M
|
41.5
Composite
|
$1.99
|
Growth
58.5
|
|
Shell Companies
|
332.73M
|
53.1
Composite
|
$10.86
|
Profitability
64.5
|
|
Shell Companies
|
331.20M
|
41.0
Composite
|
$10.80
|
Profitability
51.6
|
|
Shell Companies
|
330.09M
|
61.3
Composite
|
$10.54
|
Growth
98.9
|
|
Shell Companies
|
330.00M
|
52.3
Composite
|
$10.75
|
Profitability
66.5
|
|
Biotechnology
|
329.20M
|
60.0
Composite
|
$5.77
|
Growth
76.4
|
|
Biotechnology
|
325.96M
|
50.9
Composite
|
$1.81
|
Health
60.1
|
|
Shell Companies
|
322.61M
|
63.0
Composite
|
$10.51
|
Growth
100.0
|
|
Biotechnology
|
319.49M
|
40.8
Composite
|
$23.62
|
Valuation
56.6
|
|
Shell Companies
|
317.80M
|
66.1
Composite
|
$10.63
|
Efficiency
83.2
|
|
Shell Companies
|
315.76M
|
53.6
Composite
|
$10.70
|
Profitability
80.5
|
|
Shell Companies
|
313.36M
|
59.7
Composite
|
$10.59
|
Growth
100.0
|
|
GRAF
Graf Global Corp.
Shell Companies
|
312.66M
|
50.4
Composite
|
$10.88
|
Profitability
68.9
|
|
Shell Companies
|
309.93M
|
48.2
Composite
|
$10.78
|
Profitability
75.3
|
|
Biotechnology
|
309.50M
|
61.2
Composite
|
$3.12
|
Profitability
82.6
|
|
Shell Companies
|
308.64M
|
51.8
Composite
|
$10.58
|
Growth
100.0
|
|
Biotechnology
|
306.24M
|
43.9
Composite
|
$12.52
|
Efficiency
55.6
|
|
Shell Companies
|
305.32M
|
60.9
Composite
|
$10.62
|
Growth
100.0
|
|
Biotechnology
|
303.51M
|
56.3
Composite
|
$9.72
|
Profitability
78.4
|
|
ACIU
AC Immune SA
Biotechnology
|
302.20M
|
42.6
Composite
|
$2.92
|
Profitability
51.0
|
|
RZLT
Rezolute, Inc.
Biotechnology
|
300.50M
|
54.0
Composite
|
$3.09
|
Profitability
60.0
|
|
Biotechnology
|
300.04M
|
53.5
Composite
|
$4.23
|
Profitability
60.8
|
|
Biotechnology
|
296.70M
|
51.8
Composite
|
$3.03
|
Health
62.8
|
|
Biotechnology
|
295.67M
|
53.0
Composite
|
$5.37
|
Profitability
66.4
|
|
Biotechnology
|
293.23M
|
43.3
Composite
|
$3.86
|
Growth
60.3
|
|
Shell Companies
|
286.67M
|
50.4
Composite
|
$10.75
|
Profitability
72.5
|
|
Biotechnology
|
285.90M
|
50.0
Composite
|
$2.98
|
Profitability
60.7
|
|
Biotechnology
|
285.40M
|
46.0
Composite
|
$6.12
|
Profitability
65.2
|
|
Shell Companies
|
285.34M
|
59.8
Composite
|
$11.06
|
Profitability
84.2
|
|
Biotechnology
|
282.50M
|
44.0
Composite
|
$2.43
|
Efficiency
59.6
|
|
Shell Companies
|
281.87M
|
64.9
Composite
|
$10.53
|
Growth
100.0
|
|
CLLS
Cellectis S.A.
Biotechnology
|
279.20M
|
60.0
Composite
|
$3.86
|
Profitability
81.8
|
|
Shell Companies
|
277.66M
|
60.1
Composite
|
$10.70
|
Growth
100.0
|
|
Shell Companies
|
277.56M
|
52.5
Composite
|
$45.34
|
Profitability
68.8
|
|
Biotechnology
|
275.79M
|
46.2
Composite
|
$3.34
|
Health
55.2
|
|
SBXD
SilverBox Corp IV
Shell Companies
|
274.66M
|
49.5
Composite
|
$10.75
|
Profitability
64.7
|
|
Shell Companies
|
271.31M
|
49.9
Composite
|
$11.20
|
Profitability
74.6
|
|
Shell Companies
|
271.16M
|
45.3
Composite
|
$10.42
|
Growth
100.0
|
|
ALEC
Alector, Inc.
Biotechnology
|
270.90M
|
45.0
Composite
|
$2.44
|
Health
57.0
|
|
Shell Companies
|
270.00M
|
68.9
Composite
|
$10.35
|
Growth
83.6
|
|
Shell Companies
|
269.54M
|
49.0
Composite
|
$10.57
|
Profitability
70.4
|
|
Shell Companies
|
269.37M
|
39.6
Composite
|
$10.53
|
Growth
100.0
|
|
Biotechnology
|
267.05M
|
61.4
Composite
|
$4.09
|
Growth
82.2
|
|
Biotechnology
|
265.26M
|
59.3
Composite
|
$10.32
|
Valuation
63.1
|
|
Biotechnology
|
262.30M
|
43.8
Composite
|
$1.76
|
Health
52.9
|
|
CGEN
Compugen Ltd.
Biotechnology
|
261.00M
|
56.0
Composite
|
$2.86
|
Profitability
68.3
|
|
Shell Companies
|
260.82M
|
59.1
Composite
|
$10.61
|
Profitability
72.7
|
|
Shell Companies
|
259.26M
|
69.3
Composite
|
$7.68
|
Growth
100.0
|
|
Shell Companies
|
257.46M
|
61.6
Composite
|
$10.62
|
Growth
100.0
|
|
Biotechnology
|
255.60M
|
46.3
Composite
|
$4.79
|
Profitability
58.8
|
|
Shell Companies
|
255.39M
|
62.2
Composite
|
$10.59
|
Growth
100.0
|
|
Biotechnology
|
253.00M
|
58.3
Composite
|
$8.90
|
Profitability
76.1
|
|
Biotechnology
|
251.63M
|
46.6
Composite
|
$1.87
|
Efficiency
56.8
|
|
Biotechnology
|
247.50M
|
57.5
Composite
|
$6.90
|
Profitability
81.0
|
|
Shell Companies
|
247.02M
|
58.0
Composite
|
$10.74
|
Profitability
78.0
|
|
Biotechnology
|
247.00M
|
55.9
Composite
|
$1.24
|
Profitability
69.9
|
|
Biotechnology
|
246.54M
|
57.8
Composite
|
$4.20
|
Profitability
73.4
|
|
Biotechnology
|
241.62M
|
51.6
Composite
|
$1.89
|
Profitability
63.1
|
|
HUMA
Humacyte, Inc.
Biotechnology
|
239.78M
|
51.2
Composite
|
$1.08
|
Efficiency
61.0
|
|
Biotechnology
|
239.75M
|
39.6
Composite
|
$8.16
|
Profitability
47.9
|
|
ADAG
Adagene Inc.
Biotechnology
|
238.52M
|
39.3
Composite
|
$3.58
|
Health
57.8
|
|
Biotechnology
|
236.00M
|
49.6
Composite
|
$3.96
|
Profitability
65.0
|
|
CDXS
Codexis, Inc.
Biotechnology
|
234.40M
|
47.3
Composite
|
$2.58
|
Profitability
58.0
|
|
Shell Companies
|
233.95M
|
52.4
Composite
|
$10.82
|
Profitability
72.5
|
|
Biotechnology
|
233.10M
|
69.6
Composite
|
$11.64
|
Profitability
77.5
|
|
Biotechnology
|
229.99M
|
45.7
Composite
|
$3.93
|
Health
59.0
|
|
Biotechnology
|
225.36M
|
53.2
Composite
|
$4.34
|
Growth
66.8
|
|
Shell Companies
|
224.67M
|
62.8
Composite
|
$6.74
|
Profitability
65.1
|
|
NKTX
Nkarta, Inc.
Biotechnology
|
224.57M
|
55.3
Composite
|
$3.15
|
Profitability
66.8
|
|
MDWD
MediWound Ltd.
Biotechnology
|
221.96M
|
65.0
Composite
|
$17.27
|
Profitability
74.4
|
|
Biotechnology
|
214.08M
|
51.7
Composite
|
$2.33
|
Growth
62.0
|
|
Shell Companies
|
212.80M
|
59.4
Composite
|
$10.64
|
Growth
100.0
|
|
OABI
OmniAb, Inc.
Biotechnology
|
207.04M
|
55.2
Composite
|
$1.47
|
Profitability
66.0
|
|
Biotechnology
|
205.18M
|
45.3
Composite
|
$7.86
|
Efficiency
59.2
|
|
Biotechnology
|
203.09M
|
42.0
Composite
|
$12.96
|
Efficiency
58.2
|
|
THAR
Tharimmune, Inc.
Biotechnology
|
198.86M
|
41.9
Composite
|
$3.51
|
Growth
63.7
|
|
Biotechnology
|
193.70M
|
45.8
Composite
|
$10.87
|
Health
56.9
|
|
Biotechnology
|
193.70M
|
47.6
Composite
|
$69.54
|
Profitability
53.9
|
|
Biotechnology
|
193.59M
|
54.8
Composite
|
$0.80
|
Profitability
72.9
|
|
Biotechnology
|
193.48M
|
51.3
Composite
|
$13.62
|
Health
60.9
|
|
Biotechnology
|
193.01M
|
38.4
Composite
|
$7.48
|
Valuation
54.4
|
|
KRRO
Korro Bio, Inc.
Biotechnology
|
192.40M
|
49.8
Composite
|
$12.89
|
Profitability
53.3
|
|
Biotechnology
|
187.61M
|
43.3
Composite
|
$1.51
|
Efficiency
59.5
|
|
MGNX
MacroGenics, Inc.
Biotechnology
|
186.90M
|
59.2
Composite
|
$2.94
|
Profitability
84.9
|
|
Shell Companies
|
186.47M
|
52.7
Composite
|
$10.80
|
Profitability
72.5
|
|
Biotechnology
|
184.73M
|
50.6
Composite
|
$1.88
|
Valuation
55.9
|
|
Biotechnology
|
184.14M
|
47.7
Composite
|
$10.01
|
Health
55.6
|
|
Biotechnology
|
184.10M
|
52.3
Composite
|
$0.85
|
Profitability
63.5
|
|
IFRX
InflaRx N.V.
Biotechnology
|
180.70M
|
41.1
Composite
|
$2.65
|
Efficiency
64.2
|
|
Biotechnology
|
179.67M
|
53.0
Composite
|
$0.74
|
Profitability
69.8
|
|
Biotechnology
|
178.40M
|
42.0
Composite
|
$2.47
|
Efficiency
60.4
|
|
Shell Companies
|
169.84M
|
61.3
Composite
|
$10.61
|
Growth
82.5
|
|
Shell Companies
|
169.08M
|
53.4
Composite
|
$10.60
|
Profitability
64.6
|
|
Biotechnology
|
166.50M
|
56.0
Composite
|
$1.58
|
Profitability
69.9
|
|
Biotechnology
|
165.58M
|
49.9
Composite
|
$4.60
|
Efficiency
61.7
|
|
Biotechnology
|
165.50M
|
38.0
Composite
|
$8.85
|
Profitability
51.6
|
|
Biotechnology
|
161.55M
|
59.8
Composite
|
$2.72
|
Profitability
76.5
|
|
Biotechnology
|
159.97M
|
44.9
Composite
|
$3.96
|
Valuation
53.2
|
|
IMUX
Immunic, Inc.
Biotechnology
|
159.80M
|
36.1
Composite
|
$11.75
|
Growth
47.7
|
|
Biotechnology
|
159.50M
|
61.8
Composite
|
$1.98
|
Profitability
85.2
|
|
Biotechnology
|
158.50M
|
68.0
Composite
|
$3.91
|
Profitability
83.3
|
|
Biotechnology
|
157.48M
|
47.4
Composite
|
$4.10
|
Profitability
58.9
|
|
EDSA
Edesa Biotech, Inc.
Biotechnology
|
154.88M
|
53.4
Composite
|
$17.43
|
Profitability
59.3
|
|
Biotechnology
|
152.87M
|
38.3
Composite
|
$56.57
|
Efficiency
51.5
|
|
Biotechnology
|
152.59M
|
42.6
Composite
|
$2.40
|
Efficiency
61.9
|
|
Biotechnology
|
148.10M
|
38.5
Composite
|
$2.11
|
Efficiency
53.6
|
|
Biotechnology
|
145.30M
|
56.5
Composite
|
$2.51
|
Profitability
69.2
|
|
Biotechnology
|
144.82M
|
57.0
Composite
|
$8.24
|
Profitability
75.2
|
|
AGEN
Agenus Inc.
Biotechnology
|
144.00M
|
44.6
Composite
|
$3.75
|
Profitability
60.8
|
|
PYXS
Pyxis Oncology, Inc.
Biotechnology
|
142.00M
|
49.4
Composite
|
$2.26
|
Profitability
55.8
|
|
Biotechnology
|
140.17M
|
43.3
Composite
|
$2.33
|
Growth
51.4
|
|
IPHA
Innate Pharma S.A.
Biotechnology
|
139.82M
|
42.7
Composite
|
$1.37
|
Efficiency
51.3
|
|
ACOG
Alpha Cognition Inc.
Biotechnology
|
138.92M
|
55.0
Composite
|
$6.09
|
Profitability
80.8
|
|
Biotechnology
|
137.20M
|
53.7
Composite
|
$2.14
|
Profitability
71.8
|
|
Biotechnology
|
128.50M
|
67.9
Composite
|
$5.60
|
Profitability
88.0
|
|
GNLX
Genelux Corporation
Biotechnology
|
125.57M
|
45.2
Composite
|
$2.83
|
Efficiency
64.4
|
|
Shell Companies
|
124.95M
|
59.1
Composite
|
$11.28
|
Profitability
77.2
|
|
PEPG
PepGen Inc.
Biotechnology
|
123.81M
|
56.4
Composite
|
$1.79
|
Health
58.8
|
|
BMEA
Biomea Fusion, Inc.
Biotechnology
|
117.85M
|
52.0
Composite
|
$1.63
|
Health
59.8
|
|
Shell Companies
|
117.71M
|
55.4
Composite
|
$10.77
|
Profitability
74.1
|
|
GUTS
Fractyl Health, Inc.
Biotechnology
|
116.64M
|
32.7
Composite
|
$0.75
|
Valuation
52.0
|
|
Biotechnology
|
110.60M
|
49.1
Composite
|
$35.73
|
Profitability
56.0
|
|
CBUS
Cibus, Inc.
Biotechnology
|
110.00M
|
42.3
Composite
|
$1.50
|
Health
57.2
|
|
Biotechnology
|
109.40M
|
42.1
Composite
|
$1.60
|
Efficiency
57.2
|
|
KALA
KALA BIO, Inc.
Biotechnology
|
106.90M
|
34.7
Composite
|
$0.08
|
Efficiency
57.0
|
|
SEER
Seer, Inc.
Biotechnology
|
106.07M
|
53.7
Composite
|
$1.88
|
Profitability
65.5
|
|
Biotechnology
|
104.70M
|
51.1
Composite
|
$1.73
|
Efficiency
59.5
|
|
Biotechnology
|
104.50M
|
43.6
Composite
|
$0.90
|
Health
57.9
|
|
FGMC
FG Merger II Corp.
Shell Companies
|
104.39M
|
60.3
Composite
|
$10.25
|
Efficiency
92.4
|
|
Biotechnology
|
103.65M
|
53.0
Composite
|
$1.16
|
Growth
76.0
|
|
VANI
Vivani Medical, Inc.
Biotechnology
|
102.42M
|
47.8
Composite
|
$1.21
|
Valuation
59.6
|
|
ATYR
aTyr Pharma, Inc.
Biotechnology
|
102.00M
|
42.4
Composite
|
$0.92
|
Valuation
56.2
|
|
NRXS
Neuraxis, Inc.
Biotechnology
|
101.36M
|
52.5
Composite
|
$8.80
|
Growth
55.7
|
|
Biotechnology
|
101.20M
|
39.8
Composite
|
$3.06
|
Profitability
47.5
|
|
Shell Companies
|
99.79M
|
67.6
Composite
|
$10.41
|
Growth
96.7
|
|
Biotechnology
|
99.46M
|
61.5
Composite
|
$4.20
|
Profitability
80.7
|
|
Biotechnology
|
99.20M
|
40.4
Composite
|
$2.96
|
Efficiency
53.9
|
|
Shell Companies
|
98.71M
|
50.9
Composite
|
$11.40
|
Efficiency
66.7
|
|
Biotechnology
|
98.64M
|
49.2
Composite
|
$9.83
|
Growth
70.0
|
|
Biotechnology
|
95.83M
|
41.1
Composite
|
$0.93
|
Efficiency
65.9
|
|
Biotechnology
|
94.70M
|
32.7
Composite
|
$1.37
|
Efficiency
45.9
|
|
QTTB
Q32 Bio Inc.
Biotechnology
|
92.24M
|
52.1
Composite
|
$5.44
|
Profitability
69.5
|
|
Shell Companies
|
91.11M
|
62.6
Composite
|
$10.93
|
Valuation
70.2
|
|
Shell Companies
|
90.79M
|
42.2
Composite
|
$12.65
|
Valuation
60.1
|
|
ACET
Adicet Bio, Inc.
Biotechnology
|
89.43M
|
41.8
Composite
|
$8.32
|
Profitability
55.3
|
|
OKYO
OKYO Pharma Limited
Biotechnology
|
88.17M
|
49.3
Composite
|
$1.62
|
Profitability
68.4
|
|
PYPD
PolyPid Ltd.
Biotechnology
|
85.49M
|
44.5
Composite
|
$4.43
|
Valuation
60.1
|
|
Shell Companies
|
84.88M
|
50.5
Composite
|
$10.95
|
Profitability
61.4
|
|
EXOZ
eXoZymes, Inc.
Biotechnology
|
84.79M
|
49.7
Composite
|
$10.00
|
Efficiency
59.1
|
|
Shell Companies
|
84.69M
|
52.5
Composite
|
$10.75
|
Growth
79.0
|
|
Biotechnology
|
83.00M
|
61.0
Composite
|
$5.99
|
Profitability
88.2
|
|
ANVS
Annovis Bio, Inc.
Biotechnology
|
82.88M
|
45.3
Composite
|
$2.26
|
Growth
63.2
|
|
Biotechnology
|
82.10M
|
65.1
Composite
|
$2.40
|
Profitability
78.5
|
|
Biotechnology
|
81.90M
|
45.5
Composite
|
$4.67
|
Growth
62.6
|
|
Shell Companies
|
81.63M
|
53.8
Composite
|
$10.81
|
Profitability
69.3
|
|
Biotechnology
|
81.47M
|
45.9
Composite
|
$1.87
|
Valuation
62.5
|
|
Biotechnology
|
80.98M
|
50.5
Composite
|
$2.03
|
Profitability
57.8
|
|
GOSS
Gossamer Bio, Inc.
Biotechnology
|
80.67M
|
44.5
Composite
|
$0.34
|
Profitability
51.8
|
|
Biotechnology
|
79.48M
|
40.3
Composite
|
$1.31
|
Growth
53.5
|
|
Shell Companies
|
78.77M
|
46.2
Composite
|
$12.51
|
Efficiency
66.3
|
|
XBIT
XBiotech Inc.
Biotechnology
|
77.70M
|
53.3
Composite
|
$2.50
|
Profitability
72.5
|
|
Biotechnology
|
77.33M
|
52.0
Composite
|
$1.42
|
Valuation
56.0
|
|
RLYB
Rallybio Corporation
Biotechnology
|
77.02M
|
64.5
Composite
|
$14.66
|
Profitability
73.5
|
|
ICCC
ImmuCell Corporation
Biotechnology
|
76.63M
|
58.9
Composite
|
$8.47
|
Profitability
78.2
|
|
Biotechnology
|
76.40M
|
60.7
Composite
|
$3.29
|
Profitability
87.5
|
|
Biotechnology
|
76.16M
|
46.2
Composite
|
$1.24
|
Health
52.5
|
|
Biotechnology
|
75.13M
|
47.3
Composite
|
$1.21
|
Efficiency
60.4
|
|
Biotechnology
|
74.80M
|
49.3
Composite
|
$7.72
|
Health
67.3
|
|
EURKU
Eureka Acquisition Corp
Shell Companies
|
72.60M
|
47.1
Composite
|
$10.89
|
Efficiency
55.0
|
|
Biotechnology
|
71.98M
|
65.5
Composite
|
$13.49
|
Profitability
77.7
|
|
Biotechnology
|
71.47M
|
47.8
Composite
|
$1.70
|
Efficiency
61.8
|
|
Biotechnology
|
70.90M
|
50.3
Composite
|
$3.34
|
Growth
75.6
|
|
MNOV
MediciNova, Inc.
Biotechnology
|
70.40M
|
42.7
Composite
|
$1.43
|
Health
52.6
|
|
Biotechnology
|
69.60M
|
55.9
Composite
|
$1.36
|
Profitability
61.6
|
|
Biotechnology
|
69.45M
|
50.4
Composite
|
$16.40
|
Health
56.0
|
|
Shell Companies
|
68.23M
|
51.3
Composite
|
$10.97
|
Profitability
73.2
|
|
Biotechnology
|
67.61M
|
39.4
Composite
|
$0.63
|
Efficiency
51.4
|
|
Shell Companies
|
66.52M
|
49.2
Composite
|
$12.08
|
Valuation
57.1
|
|
CING
Cingulate Inc.
Biotechnology
|
64.07M
|
46.9
Composite
|
$5.23
|
Health
57.2
|
|
BYSI
BeyondSpring, Inc.
Biotechnology
|
63.70M
|
52.0
Composite
|
$1.42
|
Profitability
73.3
|
|
IMMP
Immutep Limited
Biotechnology
|
63.70M
|
42.7
Composite
|
$0.43
|
Growth
60.1
|
|
Shell Companies
|
62.50M
|
56.1
Composite
|
$1.23
|
Valuation
73.6
|
|
IBAC
IB Acquisition Corp.
Shell Companies
|
62.16M
|
44.9
Composite
|
$10.83
|
Efficiency
69.5
|
|
IBIO
iBio, Inc.
Biotechnology
|
61.10M
|
45.7
Composite
|
$1.64
|
Growth
62.8
|
|
Biotechnology
|
59.16M
|
44.7
Composite
|
$1.14
|
Health
61.3
|
|
ENTX
Entera Bio Ltd.
Biotechnology
|
58.28M
|
49.3
Composite
|
$1.37
|
Growth
63.0
|
|
Shell Companies
|
58.17M
|
55.4
Composite
|
$11.00
|
Profitability
73.1
|
|
Biotechnology
|
56.21M
|
48.7
Composite
|
$0.52
|
Growth
69.1
|
|
Biotechnology
|
55.67M
|
50.1
Composite
|
$11.19
|
Profitability
73.4
|
|
Biotechnology
|
55.60M
|
37.4
Composite
|
$0.10
|
Health
55.5
|
|
Biotechnology
|
55.46M
|
38.1
Composite
|
$1.27
|
Profitability
59.9
|
|
Shell Companies
|
55.13M
|
51.7
Composite
|
$10.97
|
Profitability
73.8
|
|
Biotechnology
|
55.11M
|
38.9
Composite
|
$1.56
|
Profitability
51.0
|
|
Shell Companies
|
54.82M
|
49.0
Composite
|
$11.36
|
Efficiency
93.0
|
|
Biotechnology
|
54.52M
|
47.0
Composite
|
$7.36
|
Health
56.1
|
|
TIL
Instil Bio, Inc.
Biotechnology
|
54.32M
|
52.0
Composite
|
$8.03
|
Profitability
63.5
|
|
MGX
Metagenomi, Inc.
Biotechnology
|
53.46M
|
51.2
Composite
|
$1.42
|
Profitability
65.6
|
|
Biotechnology
|
51.10M
|
42.5
Composite
|
$4.93
|
Growth
62.2
|
|
Shell Companies
|
50.33M
|
33.6
Composite
|
$11.96
|
Efficiency
55.0
|
|
ATHA
Athira Pharma, Inc.
Biotechnology
|
50.13M
|
40.9
Composite
|
$7.66
|
Growth
55.8
|
|
Shell Companies
|
50.11M
|
56.0
Composite
|
$7.90
|
Growth
97.8
|
|
Biotechnology
|
49.90M
|
45.1
Composite
|
$5.67
|
Health
59.2
|
|
Shell Companies
|
49.26M
|
51.4
Composite
|
$11.86
|
Valuation
67.5
|
|
Biotechnology
|
46.73M
|
55.1
Composite
|
$7.81
|
Profitability
71.7
|
|
Shell Companies
|
46.29M
|
42.4
Composite
|
$10.80
|
Profitability
49.8
|
|
NTRB
Nutriband Inc.
Biotechnology
|
46.10M
|
40.2
Composite
|
$3.79
|
Valuation
49.1
|
|
Biotechnology
|
46.00M
|
44.0
Composite
|
$2.91
|
Growth
63.5
|
|
Shell Companies
|
45.41M
|
52.2
Composite
|
$7.63
|
Profitability
76.4
|
|
Biotechnology
|
45.38M
|
54.0
Composite
|
$1.32
|
Growth
91.8
|
|
Shell Companies
|
45.15M
|
37.1
Composite
|
$11.57
|
Health
55.0
|
|
Biotechnology
|
43.90M
|
51.1
Composite
|
$1.53
|
Profitability
59.1
|
|
Shell Companies
|
43.64M
|
40.2
Composite
|
$12.20
|
Valuation
50.1
|
|
MEIP
MEI Pharma, Inc.
Biotechnology
|
43.30M
|
0.0
Composite
|
$1.14
|
No pillar score
-
|
|
Shell Companies
|
43.10M
|
49.5
Composite
|
$11.50
|
Efficiency
79.6
|
|
Biotechnology
|
42.10M
|
49.0
Composite
|
$9.93
|
Profitability
67.8
|
|
Biotechnology
|
41.20M
|
51.5
Composite
|
$5.95
|
Health
59.9
|
|
Shell Companies
|
40.99M
|
52.6
Composite
|
$11.22
|
Profitability
59.9
|
|
RNXT
RenovoRx, Inc.
Biotechnology
|
40.09M
|
52.3
Composite
|
$0.88
|
Profitability
55.9
|
|
Biotechnology
|
39.42M
|
38.2
Composite
|
$6.03
|
Efficiency
50.8
|
|
Shell Companies
|
38.67M
|
26.8
Composite
|
$12.55
|
Efficiency
47.9
|
|
Biotechnology
|
38.31M
|
45.0
Composite
|
$0.24
|
Efficiency
65.6
|
|
Biotechnology
|
38.30M
|
45.4
Composite
|
$1.22
|
Growth
53.9
|
|
Shell Companies
|
38.13M
|
32.0
Composite
|
$13.27
|
Valuation
67.3
|
|
INMB
INmune Bio Inc.
Biotechnology
|
38.02M
|
50.4
Composite
|
$1.43
|
Growth
63.3
|
|
Shell Companies
|
37.05M
|
37.6
Composite
|
$13.45
|
Health
54.6
|
|
EVAX
Evaxion Biotech A/S
Biotechnology
|
36.78M
|
61.6
Composite
|
$4.07
|
Growth
77.1
|
|
SNPX
Synaptogenix, Inc.
Biotechnology
|
36.76M
|
0.0
Composite
|
$24.55
|
No pillar score
-
|
|
NXTC
NextCure, Inc.
Biotechnology
|
36.72M
|
48.5
Composite
|
$10.18
|
Health
60.1
|
|
Biotechnology
|
36.70M
|
52.4
Composite
|
$2.37
|
Growth
61.3
|
|
VERU
Veru Inc.
Biotechnology
|
35.60M
|
52.4
Composite
|
$2.28
|
Profitability
63.0
|
|
BOLD
Boundless Bio, Inc.
Biotechnology
|
35.42M
|
46.3
Composite
|
$1.53
|
Profitability
54.7
|
|
CRVO
CervoMed Inc.
Biotechnology
|
35.18M
|
50.7
Composite
|
$3.80
|
Profitability
69.8
|
|
APLM
Apollomics Inc.
Biotechnology
|
34.92M
|
38.2
Composite
|
$15.90
|
Profitability
54.7
|
|
Biotechnology
|
34.88M
|
46.0
Composite
|
$23.76
|
Profitability
57.4
|
|
Biotechnology
|
33.70M
|
41.2
Composite
|
$18.90
|
Valuation
53.9
|
|
Biotechnology
|
33.60M
|
32.9
Composite
|
$1.24
|
Efficiency
57.3
|
|
PLUR
Pluri Inc.
Biotechnology
|
33.20M
|
38.9
Composite
|
$3.34
|
Efficiency
63.4
|
|
Biotechnology
|
32.80M
|
49.6
Composite
|
$1.17
|
Efficiency
64.2
|
|
Shell Companies
|
32.67M
|
51.7
Composite
|
$11.89
|
Efficiency
73.2
|
|
Biotechnology
|
31.74M
|
34.4
Composite
|
$0.88
|
Profitability
39.7
|
|
IGC
IGC Pharma, Inc.
Biotechnology
|
31.40M
|
47.3
Composite
|
$0.32
|
Efficiency
59.0
|
|
Biotechnology
|
31.15M
|
46.8
Composite
|
$7.48
|
Profitability
60.1
|
|
NNVC
NanoViricides, Inc.
Biotechnology
|
30.70M
|
53.4
Composite
|
$1.42
|
Growth
75.7
|
|
Biotechnology
|
30.25M
|
39.5
Composite
|
$0.98
|
Efficiency
65.1
|
|
Biotechnology
|
30.13M
|
45.1
Composite
|
$0.62
|
Efficiency
64.5
|
|
Biotechnology
|
29.70M
|
36.7
Composite
|
$4.10
|
Growth
56.2
|
|
Biotechnology
|
29.40M
|
45.8
Composite
|
$3.23
|
Health
57.4
|
|
Shell Companies
|
29.15M
|
34.3
Composite
|
$7.33
|
Valuation
54.2
|
|
Biotechnology
|
29.00M
|
52.1
Composite
|
$5.34
|
Profitability
67.8
|
|
Shell Companies
|
28.62M
|
29.4
Composite
|
$12.50
|
Valuation
49.8
|
|
Biotechnology
|
28.40M
|
40.4
Composite
|
$0.90
|
Valuation
56.0
|
|
Biotechnology
|
28.26M
|
50.9
Composite
|
$1.97
|
Growth
63.6
|
|
ABVC
ABVC Biopharma, Inc.
Biotechnology
|
28.00M
|
51.0
Composite
|
$1.10
|
Profitability
80.0
|
|
FGEN
FibroGen, Inc
Biotechnology
|
27.90M
|
52.0
Composite
|
$7.21
|
Profitability
62.9
|
|
Biotechnology
|
27.70M
|
50.7
Composite
|
$0.75
|
Valuation
57.1
|
|
Shell Companies
|
27.52M
|
35.8
Composite
|
$9.19
|
Efficiency
47.9
|
|
Biotechnology
|
27.26M
|
42.5
Composite
|
$1.81
|
Valuation
63.5
|
|
Shell Companies
|
26.88M
|
66.6
Composite
|
$11.40
|
Growth
95.5
|
|
Biotechnology
|
26.86M
|
47.0
Composite
|
$0.67
|
Profitability
62.6
|
|
Biotechnology
|
26.51M
|
45.7
Composite
|
$0.95
|
Health
64.1
|
|
PLRZ
Polyrizon Ltd.
Biotechnology
|
26.47M
|
57.8
Composite
|
$14.14
|
Efficiency
71.2
|
|
CELU
Celularity Inc.
Biotechnology
|
26.17M
|
39.1
Composite
|
$0.91
|
Profitability
56.2
|
|
NKGN
NKGen Biotech, Inc.
Biotechnology
|
26.12M
|
41.0
Composite
|
$0.06
|
Valuation
52.0
|
|
LGVN
Longeveron Inc.
Biotechnology
|
24.94M
|
39.9
Composite
|
$0.85
|
Efficiency
59.9
|
|
CRIS
Curis, Inc.
Biotechnology
|
24.70M
|
45.9
Composite
|
$0.58
|
Profitability
62.5
|
|
Biotechnology
|
24.30M
|
57.4
Composite
|
$1.44
|
Profitability
66.0
|
|
Biotechnology
|
24.25M
|
51.3
Composite
|
$0.22
|
Efficiency
75.0
|
|
Biotechnology
|
24.20M
|
40.3
Composite
|
$0.59
|
Growth
48.9
|
|
LTRN
Lantern Pharma Inc.
Biotechnology
|
23.99M
|
49.9
Composite
|
$2.04
|
Efficiency
64.0
|
|
Biotechnology
|
23.19M
|
50.0
Composite
|
$1.50
|
Efficiency
77.3
|
|
AEON
AEON Biopharma, Inc.
Biotechnology
|
22.91M
|
46.7
Composite
|
$0.91
|
Growth
66.1
|
|
Shell Companies
|
22.51M
|
40.7
Composite
|
$4.98
|
Profitability
53.4
|
|
Biotechnology
|
22.44M
|
42.9
Composite
|
$0.67
|
Efficiency
62.5
|
|
XCUR
Exicure, Inc.
Biotechnology
|
21.35M
|
46.7
Composite
|
$3.35
|
Efficiency
58.0
|
|
Biotechnology
|
21.20M
|
46.7
Composite
|
$0.84
|
Profitability
55.9
|
|
Biotechnology
|
19.89M
|
40.1
Composite
|
$1.30
|
Efficiency
51.5
|
|
Biotechnology
|
19.47M
|
48.2
Composite
|
$4.86
|
Growth
67.5
|
|
Biotechnology
|
19.40M
|
38.8
Composite
|
$1.39
|
Growth
55.3
|
|
Biotechnology
|
18.99M
|
38.7
Composite
|
$6.02
|
Valuation
52.9
|
|
Biotechnology
|
18.86M
|
48.2
Composite
|
$0.46
|
Growth
59.3
|
|
LPCN
Lipocine Inc.
Biotechnology
|
17.70M
|
41.8
Composite
|
$2.39
|
Growth
50.0
|
|
TRAW
Traws Pharma, Inc.
Biotechnology
|
17.27M
|
45.8
Composite
|
$1.70
|
Growth
54.5
|
|
Biotechnology
|
16.50M
|
44.4
Composite
|
$0.36
|
Health
47.9
|
|
Biotechnology
|
15.90M
|
43.6
Composite
|
$0.64
|
Growth
56.0
|
|
INAB
IN8bio, Inc.
Biotechnology
|
15.76M
|
55.4
Composite
|
$1.60
|
Growth
60.0
|
|
BLRX
BioLineRx Ltd.
Biotechnology
|
15.25M
|
63.2
Composite
|
$3.10
|
Profitability
72.6
|
|
Biotechnology
|
15.10M
|
44.3
Composite
|
$0.64
|
Health
57.1
|
|
Biotechnology
|
14.90M
|
46.6
Composite
|
$0.65
|
Profitability
53.5
|
|
HOOK
HOOKIPA Pharma Inc.
Biotechnology
|
14.18M
|
56.0
Composite
|
$1.19
|
Profitability
67.5
|
|
Biotechnology
|
14.14M
|
38.8
Composite
|
$0.69
|
Efficiency
42.9
|
|
Biotechnology
|
14.00M
|
39.9
Composite
|
$3.30
|
Growth
55.6
|
|
Biotechnology
|
13.69M
|
52.6
Composite
|
$3.15
|
Profitability
67.7
|
|
Biotechnology
|
13.60M
|
38.8
Composite
|
$6.02
|
Profitability
59.2
|
|
Biotechnology
|
13.30M
|
35.4
Composite
|
$2.49
|
Health
43.3
|
|
Biotechnology
|
13.24M
|
47.3
Composite
|
$1.14
|
Growth
60.5
|
|
PASG
Passage Bio, Inc.
Biotechnology
|
13.22M
|
50.1
Composite
|
$4.08
|
Profitability
59.1
|
|
Biotechnology
|
13.17M
|
42.9
Composite
|
$0.36
|
Growth
57.7
|
|
Biotechnology
|
12.98M
|
50.2
Composite
|
$5.11
|
Health
55.0
|
|
Biotechnology
|
12.89M
|
44.5
Composite
|
$1.74
|
Profitability
55.5
|
|
GTBP
GT Biopharma, Inc.
Biotechnology
|
12.70M
|
42.5
Composite
|
$0.39
|
Efficiency
68.4
|
|
BIVI
BioVie Inc.
Biotechnology
|
12.50M
|
43.5
Composite
|
$1.66
|
Growth
53.6
|
|
Biotechnology
|
12.30M
|
42.5
Composite
|
$1.60
|
Health
59.9
|
|
BCDA
BioCardia, Inc.
Biotechnology
|
11.93M
|
39.3
Composite
|
$1.09
|
Growth
54.9
|
|
KAPA
Kairos Pharma, Ltd.
Biotechnology
|
11.88M
|
58.7
Composite
|
$0.56
|
Profitability
68.5
|
|
RENB
Renovaro Inc.
Biotechnology
|
11.60M
|
0.0
Composite
|
$0.32
|
No pillar score
-
|
|
Biotechnology
|
11.60M
|
41.0
Composite
|
$6.37
|
Health
55.2
|
|
Biotechnology
|
11.28M
|
48.5
Composite
|
$0.86
|
Efficiency
66.7
|
|
Biotechnology
|
10.89M
|
49.0
Composite
|
$0.72
|
Profitability
63.4
|
|
IMNN
Imunon, Inc.
Biotechnology
|
10.60M
|
45.4
Composite
|
$2.73
|
Health
52.8
|
|
Biotechnology
|
10.11M
|
57.7
Composite
|
$2.08
|
Growth
74.2
|
|
Biotechnology
|
9.99M
|
50.2
Composite
|
$0.88
|
Profitability
58.0
|
|
Biotechnology
|
9.90M
|
55.1
Composite
|
$2.45
|
Profitability
76.6
|
|
CALC
CalciMedica, Inc.
Biotechnology
|
9.80M
|
37.9
Composite
|
$0.64
|
Efficiency
54.9
|
|
ELAB
PMGC Holdings Inc.
Biotechnology
|
9.48M
|
46.5
Composite
|
$2.16
|
Valuation
50.5
|
|
NCNA
NuCana plc
Biotechnology
|
9.20M
|
52.9
Composite
|
$2.09
|
Growth
74.9
|
|
Biotechnology
|
8.82M
|
50.0
Composite
|
$4.59
|
Profitability
59.9
|
|
Biotechnology
|
8.61M
|
43.4
Composite
|
$0.69
|
Profitability
52.4
|
|
Biotechnology
|
8.60M
|
46.0
Composite
|
$0.80
|
Valuation
53.8
|
|
EVGN
Evogene Ltd.
Biotechnology
|
8.36M
|
58.6
Composite
|
$0.78
|
Profitability
66.8
|
|
Biotechnology
|
8.20M
|
45.9
Composite
|
$2.29
|
Valuation
51.8
|
|
GNPX
Genprex, Inc.
Biotechnology
|
8.00M
|
37.3
Composite
|
$0.86
|
Health
55.7
|
|
Biotechnology
|
7.67M
|
47.3
Composite
|
$2.12
|
Growth
70.6
|
|
Biotechnology
|
7.48M
|
54.7
Composite
|
$2.67
|
Profitability
68.3
|
|
Biotechnology
|
7.30M
|
42.4
Composite
|
$2.87
|
Efficiency
50.6
|
|
MTVA
MetaVia Inc.
Biotechnology
|
7.23M
|
49.7
Composite
|
$1.33
|
Health
63.2
|
|
BCAB
BioAtla, Inc.
Biotechnology
|
7.21M
|
45.5
Composite
|
$4.35
|
Profitability
53.8
|
|
Biotechnology
|
7.18M
|
37.7
Composite
|
$7.01
|
Efficiency
41.6
|
|
Biotechnology
|
7.15M
|
47.8
Composite
|
$1.38
|
Profitability
67.0
|
|
Biotechnology
|
7.10M
|
57.9
Composite
|
$3.12
|
Profitability
76.4
|
|
Biotechnology
|
7.04M
|
41.6
Composite
|
$7.82
|
Efficiency
67.9
|
|
Biotechnology
|
7.04M
|
40.5
Composite
|
$3.54
|
Valuation
54.9
|
|
SYBX
Synlogic, Inc.
Biotechnology
|
6.96M
|
41.6
Composite
|
$0.65
|
Profitability
53.4
|
|
Biotechnology
|
6.93M
|
45.7
Composite
|
$0.84
|
Growth
54.7
|
|
Biotechnology
|
6.90M
|
40.5
Composite
|
$7.65
|
Valuation
50.5
|
|
FBLG
FibroBiologics, Inc.
Biotechnology
|
6.72M
|
44.7
Composite
|
$1.24
|
Valuation
55.4
|
|
IMRN
Immuron Limited
Biotechnology
|
6.70M
|
41.8
Composite
|
$0.83
|
Profitability
55.3
|
|
Biotechnology
|
6.59M
|
42.9
Composite
|
$6.58
|
Growth
64.0
|
|
MLEC
Moolec Science SA
Biotechnology
|
6.48M
|
38.8
Composite
|
$8.98
|
Profitability
60.3
|
|
PPBT
Purple Biotech Ltd.
Biotechnology
|
6.39M
|
55.9
Composite
|
$3.91
|
Profitability
73.5
|
|
Biotechnology
|
6.31M
|
38.8
Composite
|
$3.17
|
Profitability
43.2
|
|
Biotechnology
|
6.30M
|
44.8
Composite
|
$2.67
|
Efficiency
57.8
|
|
Biotechnology
|
6.20M
|
41.5
Composite
|
$0.23
|
Efficiency
66.8
|
|
Shell Companies
|
5.87M
|
68.7
Composite
|
$0.38
|
Growth
100.0
|
|
Biotechnology
|
5.80M
|
42.6
Composite
|
$4.86
|
Health
57.3
|
|
Biotechnology
|
5.70M
|
36.8
Composite
|
$0.56
|
Efficiency
59.0
|
|
Biotechnology
|
5.60M
|
42.5
Composite
|
$7.10
|
Valuation
58.7
|
|
MBIO
Mustang Bio, Inc.
Biotechnology
|
5.50M
|
57.5
Composite
|
$0.73
|
Profitability
75.4
|
|
Biotechnology
|
5.39M
|
45.1
Composite
|
$1.81
|
Efficiency
65.8
|
|
Biotechnology
|
5.30M
|
40.2
Composite
|
$0.39
|
Efficiency
55.9
|
|
Biotechnology
|
5.11M
|
45.0
Composite
|
$1.30
|
Valuation
58.2
|
|
PHGE
BiomX Inc.
Biotechnology
|
5.03M
|
37.4
Composite
|
$0.62
|
Profitability
47.3
|
|
GOVX
GeoVax Labs, Inc.
Biotechnology
|
4.77M
|
38.7
Composite
|
$1.76
|
Valuation
45.4
|
|
PULM
Pulmatrix, Inc.
Biotechnology
|
4.75M
|
53.6
Composite
|
$1.30
|
Profitability
67.0
|
|
Biotechnology
|
4.60M
|
43.1
Composite
|
$2.03
|
Health
63.2
|
|
Biotechnology
|
4.40M
|
47.8
Composite
|
$0.65
|
Growth
63.4
|
|
Biotechnology
|
4.38M
|
46.7
Composite
|
$1.58
|
Profitability
53.6
|
|
Biotechnology
|
4.35M
|
42.7
Composite
|
$0.13
|
Efficiency
53.6
|
|
ALZN
Alzamend Neuro, Inc.
Biotechnology
|
4.19M
|
52.3
Composite
|
$1.06
|
Efficiency
86.8
|
|
Biotechnology
|
4.10M
|
59.1
Composite
|
$0.63
|
Profitability
70.9
|
|
AZTR
Azitra Inc
Biotechnology
|
3.97M
|
31.0
Composite
|
$0.24
|
Efficiency
49.9
|
|
Biotechnology
|
3.90M
|
44.8
Composite
|
$0.56
|
Efficiency
76.9
|
|
Biotechnology
|
3.79M
|
40.7
Composite
|
$1.02
|
Health
59.5
|
|
Biotechnology
|
3.72M
|
52.2
Composite
|
$8.28
|
Efficiency
98.2
|
|
SPRC
SciSparc Ltd.
Biotechnology
|
3.61M
|
33.3
Composite
|
$6.72
|
Health
43.1
|
|
Biotechnology
|
3.60M
|
36.7
Composite
|
$0.37
|
Valuation
44.8
|
|
GRI
GRI Bio, Inc.
Biotechnology
|
3.41M
|
41.4
Composite
|
$2.36
|
Profitability
48.7
|
|
SNGX
Soligenix, Inc.
Biotechnology
|
3.20M
|
41.9
Composite
|
$0.31
|
Health
55.0
|
|
Biotechnology
|
2.91M
|
41.2
Composite
|
$0.04
|
Efficiency
50.4
|
|
Biotechnology
|
2.87M
|
37.0
Composite
|
$4.86
|
Health
46.9
|
|
VCNX
Vaccinex, Inc.
Biotechnology
|
2.81M
|
33.0
Composite
|
$1.01
|
Efficiency
56.3
|
|
OGEN
Oragenics Inc.
Biotechnology
|
2.70M
|
53.7
Composite
|
$0.61
|
Growth
75.0
|
|
Biotechnology
|
2.51M
|
36.5
Composite
|
$2.68
|
Efficiency
45.9
|
|
Biotechnology
|
2.51M
|
38.8
Composite
|
$0.14
|
Efficiency
68.1
|
|
Biotechnology
|
2.43M
|
40.9
Composite
|
$0.22
|
Growth
65.2
|
|
HCWB
HCW Biologics Inc.
Biotechnology
|
2.36M
|
37.2
Composite
|
$0.32
|
Valuation
53.3
|
|
Biotechnology
|
2.26M
|
39.6
Composite
|
$1.42
|
Efficiency
53.2
|
|
Biotechnology
|
2.15M
|
43.6
Composite
|
$0.31
|
Efficiency
52.4
|
|
Biotechnology
|
1.91M
|
39.9
Composite
|
$0.52
|
Growth
61.0
|
|
Biotechnology
|
1.88M
|
48.3
Composite
|
$0.54
|
Profitability
54.0
|
|
Biotechnology
|
1.81M
|
52.8
Composite
|
$0.55
|
Profitability
69.9
|
|
Biotechnology
|
1.62M
|
39.6
Composite
|
$0.20
|
Valuation
52.8
|
|
Biotechnology
|
1.30M
|
44.5
Composite
|
$0.73
|
Efficiency
64.0
|
|
Biotechnology
|
1.29M
|
43.5
Composite
|
$0.03
|
Growth
61.1
|
|
Biotechnology
|
1.28M
|
41.1
Composite
|
$0.58
|
Efficiency
63.7
|
|
JAGX
Jaguar Health, Inc.
Biotechnology
|
1.20M
|
44.4
Composite
|
$2.98
|
Profitability
51.4
|
|
Biotechnology
|
516,620
|
42.3
Composite
|
$0.06
|
Valuation
58.0
|
|
Biotechnology
|
497,436
|
50.0
Composite
|
$2.65
|
Valuation
54.9
|
|
Biotechnology
|
441,572
|
42.3
Composite
|
$0.06
|
Growth
61.8
|
|
Shell Companies
|
366,754
|
32.3
Composite
|
$0.07
|
Efficiency
81.9
|
|
Biotechnology
|
337,087
|
41.1
Composite
|
$0.02
|
Profitability
56.7
|
|
ONCO
Onconetix, Inc.
Biotechnology
|
311,817
|
37.3
Composite
|
$0.40
|
Valuation
51.9
|
|
IOBT
IO Biotech, Inc.
Biotechnology
|
309,380
|
46.4
Composite
|
$0.00
|
Health
66.0
|
|
Biotechnology
|
161,729
|
39.6
Composite
|
$0.03
|
Growth
50.9
|
|
ADTX
Aditxt, Inc.
Biotechnology
|
122,103
|
35.4
Composite
|
$0.12
|
Valuation
49.9
|
|
Biotechnology
|
92,946
|
38.0
Composite
|
$0.00
|
Profitability
45.8
|
|
VINC
Vincerx Pharma, Inc.
Biotechnology
|
65,428
|
40.9
Composite
|
$0.01
|
Efficiency
63.1
|
|
Biotechnology
|
16,738
|
52.9
Composite
|
$0.00
|
Profitability
68.3
|
|
Biotechnology
|
12,074
|
45.7
Composite
|
$0.00
|
Efficiency
60.8
|
|
Biotechnology
|
941
|
36.1
Composite
|
$0.00
|
Efficiency
55.7
|
|
Biotechnology
|
621
|
36.0
Composite
|
$0.00
|
Efficiency
100.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
ATNFW
180 Life Sciences Corp.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
TSVT
2seventy bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
CSLMF
6816
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
ETNB
89bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
68.7
Composite
|
$11.11
|
Growth
100.0
|
|
Shell Companies
|
-
|
44.7
Composite
|
$10.66
|
Health
58.7
|
|
Biotechnology
|
-
|
53.1
Composite
|
-
|
Profitability
60.4
|
|
ABPWW
Abpro Holdings, Inc.
Biotechnology
|
-
|
42.8
Composite
|
-
|
Efficiency
61.9
|
|
SLRN
ACELYRIN, INC.
Biotechnology
|
-
|
34.1
Composite
|
-
|
Health
48.1
|
|
Biotechnology
|
-
|
51.7
Composite
|
-
|
Efficiency
59.9
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
48.1
Composite
|
-
|
Profitability
62.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
AFMD
Affimed N.V.
Biotechnology
|
-
|
34.4
Composite
|
$0.18
|
Health
53.9
|
|
Shell Companies
|
-
|
51.5
Composite
|
$11.11
|
Profitability
68.5
|
|
Shell Companies
|
-
|
51.5
Composite
|
$0.22
|
Profitability
68.5
|
|
Shell Companies
|
-
|
45.0
Composite
|
-
|
Growth
100.0
|
|
Shell Companies
|
-
|
45.0
Composite
|
-
|
Growth
100.0
|
|
Shell Companies
|
-
|
48.0
Composite
|
$54.82
|
Profitability
69.2
|
|
Shell Companies
|
-
|
0.0
Composite
|
$19.26
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$18.15
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.04
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
31.7
Composite
|
$13.50
|
Efficiency
55.0
|
|
ALDFU
Aldel Financial II Inc.
Shell Companies
|
-
|
65.8
Composite
|
$10.66
|
Growth
100.0
|
|
Shell Companies
|
-
|
61.2
Composite
|
$0.34
|
Growth
100.0
|
|
ALLK
Allakos Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
ALVR
AlloVir, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
45.1
Composite
|
$1.02
|
Efficiency
53.9
|
|
Shell Companies
|
-
|
56.5
Composite
|
-
|
Profitability
71.1
|
|
Shell Companies
|
-
|
57.6
Composite
|
-
|
Profitability
73.5
|
|
Shell Companies
|
-
|
56.2
Composite
|
-
|
Profitability
71.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
28.2
Composite
|
-
|
Profitability
45.4
|
|
Shell Companies
|
-
|
29.9
Composite
|
$12.01
|
Profitability
46.3
|
|
Shell Companies
|
-
|
28.2
Composite
|
$4.50
|
Profitability
45.4
|
|
Shell Companies
|
-
|
55.2
Composite
|
$11.67
|
Profitability
80.5
|
|
Biotechnology
|
-
|
43.5
Composite
|
-
|
Growth
57.6
|
|
Biotechnology
|
-
|
39.8
Composite
|
-
|
Efficiency
49.5
|
|
APXIU
APx Acquisition Corp. I
Shell Companies
|
-
|
36.4
Composite
|
-
|
Efficiency
89.5
|
|
Shell Companies
|
-
|
37.7
Composite
|
-
|
Efficiency
89.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
29.6
Composite
|
$12.79
|
Efficiency
38.4
|
|
Biotechnology
|
-
|
46.5
Composite
|
-
|
Efficiency
55.2
|
|
Shell Companies
|
-
|
31.4
Composite
|
-
|
Efficiency
62.1
|
|
Shell Companies
|
-
|
32.0
Composite
|
-
|
Efficiency
62.1
|
|
Shell Companies
|
-
|
32.0
Composite
|
-
|
Efficiency
62.1
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
51.9
Composite
|
-
|
Profitability
63.5
|
|
Shell Companies
|
-
|
36.4
Composite
|
-
|
Health
41.4
|
|
Shell Companies
|
-
|
36.4
Composite
|
-
|
Health
41.4
|
|
BAYAU
Bayview Acquisition Corp
Shell Companies
|
-
|
44.8
Composite
|
$11.85
|
Efficiency
73.2
|
|
BGNE
BeiGene, Ltd.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
40.0
Composite
|
-
|
Efficiency
48.8
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
39.8
Composite
|
$0.03
|
Growth
84.2
|
|
Shell Companies
|
-
|
45.8
Composite
|
$11.60
|
Profitability
67.7
|
|
Shell Companies
|
-
|
70.6
Composite
|
$11.00
|
Growth
100.0
|
|
BLEU
bleuacacia ltd
Shell Companies
|
-
|
27.0
Composite
|
-
|
Efficiency
47.3
|
|
BLEUU
bleuacacia ltd
Shell Companies
|
-
|
27.0
Composite
|
-
|
Efficiency
47.3
|
|
BLEUW
bleuacacia ltd Warrants
Shell Companies
|
-
|
39.0
Composite
|
-
|
Profitability
54.6
|
|
BLUE
bluebird bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
62.6
Composite
|
$10.76
|
Growth
100.0
|
|
Shell Companies
|
-
|
32.4
Composite
|
$0.00
|
Efficiency
81.9
|
|
BOWNU
Bowen Acquisition Corp
Shell Companies
|
-
|
35.3
Composite
|
-
|
Profitability
58.8
|
|
Biotechnology
|
-
|
42.0
Composite
|
$0.00
|
Growth
64.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
39.3
Composite
|
-
|
Health
53.6
|
|
Shell Companies
|
-
|
41.3
Composite
|
-
|
Profitability
52.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
40.6
Composite
|
$15.95
|
Profitability
55.1
|
|
Shell Companies
|
-
|
40.6
Composite
|
$0.09
|
Profitability
55.1
|
|
Shell Companies
|
-
|
44.6
Composite
|
-
|
Profitability
63.8
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
44.2
Composite
|
$0.03
|
Growth
70.3
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.69
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.75
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$183.66
|
No pillar score
-
|
|
Shell Companies
|
-
|
55.3
Composite
|
$10.91
|
Profitability
75.6
|
|
CELUW
Celularity Inc.
Biotechnology
|
-
|
41.0
Composite
|
$0.01
|
Profitability
60.6
|
|
Shell Companies
|
-
|
41.3
Composite
|
$10.80
|
Efficiency
60.2
|
|
Biotechnology
|
-
|
39.6
Composite
|
$0.00
|
Efficiency
60.1
|
|
CFFSU
CF Acquisition Corp. VII
Shell Companies
|
-
|
41.8
Composite
|
-
|
Profitability
48.6
|
|
Shell Companies
|
-
|
41.8
Composite
|
-
|
Profitability
48.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
58.0
Composite
|
$10.69
|
Growth
100.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
CMRX
Chimerix, Inc.
Biotechnology
|
-
|
45.1
Composite
|
-
|
Health
60.7
|
|
Shell Companies
|
-
|
57.5
Composite
|
$10.84
|
Profitability
84.5
|
|
Biotechnology
|
-
|
40.6
Composite
|
-
|
Valuation
45.6
|
|
CINGW
Cingulate Inc. Warrants
Biotechnology
|
-
|
46.1
Composite
|
$0.06
|
Health
57.2
|
|
CLRCU
ClimateRock
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
CLRC
ClimateRock
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
CLRCW
ClimateRock Warrant
Shell Companies
|
-
|
0.0
Composite
|
$0.03
|
No pillar score
-
|
|
Shell Companies
|
-
|
67.5
Composite
|
$11.84
|
Growth
100.0
|
|
Shell Companies
|
-
|
67.5
Composite
|
$0.11
|
Growth
100.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
39.4
Composite
|
$0.01
|
Growth
60.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
$1.94
|
No pillar score
-
|
|
CVAC
CureVac N.V.
Biotechnology
|
-
|
69.2
Composite
|
-
|
Profitability
88.1
|
|
CYBN
Cybin Inc.
Biotechnology
|
-
|
47.0
Composite
|
$7.61
|
Efficiency
59.9
|
|
Biotechnology
|
-
|
51.4
Composite
|
-
|
Profitability
75.7
|
|
Biotechnology
|
-
|
41.5
Composite
|
-
|
Growth
66.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
25.4
Composite
|
-
|
Profitability
38.5
|
|
Biotechnology
|
-
|
37.6
Composite
|
$0.02
|
Efficiency
50.4
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
22.8
Composite
|
-
|
Profitability
33.4
|
|
Shell Companies
|
-
|
22.8
Composite
|
-
|
Profitability
33.4
|
|
Shell Companies
|
-
|
22.8
Composite
|
-
|
Profitability
33.4
|
|
Shell Companies
|
-
|
20.8
Composite
|
-
|
Efficiency
61.3
|
|
Shell Companies
|
-
|
21.6
Composite
|
-
|
Efficiency
61.3
|
|
Shell Companies
|
-
|
38.7
Composite
|
-
|
Profitability
51.8
|
|
DUETU
DUET Acquisition Corp.
Shell Companies
|
-
|
38.7
Composite
|
-
|
Profitability
51.8
|
|
Shell Companies
|
-
|
38.7
Composite
|
-
|
Profitability
51.8
|
|
DYNX
Dynamix Corporation
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
DYNXU
Dynamix Corporation
Shell Companies
|
-
|
0.0
Composite
|
$10.89
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.78
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$12.80
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.00
|
No pillar score
-
|
|
Shell Companies
|
-
|
47.0
Composite
|
-
|
Profitability
56.6
|
|
Biotechnology
|
-
|
40.4
Composite
|
$2.23
|
Efficiency
56.5
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
EPIX
ESSA Pharma Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
31.8
Composite
|
$0.14
|
Profitability
45.2
|
|
EYEN
Eyenovia, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
51.5
Composite
|
$10.99
|
Efficiency
69.9
|
|
FGMCU
FG Merger II Corp.
Shell Companies
|
-
|
57.1
Composite
|
$10.75
|
Efficiency
91.3
|
|
Shell Companies
|
-
|
51.7
Composite
|
$0.16
|
Health
65.2
|
|
Shell Companies
|
-
|
35.6
Composite
|
-
|
Efficiency
77.5
|
|
Shell Companies
|
-
|
35.6
Composite
|
-
|
Efficiency
77.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
33.6
Composite
|
$11.01
|
Efficiency
66.7
|
|
FICVW
Frontier Investment Corp
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
55.4
Composite
|
-
|
Efficiency
92.5
|
|
FHLTU
Future Health ESG Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
FHLTW
Future Health ESG Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
56.9
Composite
|
$10.79
|
Profitability
69.3
|
|
Shell Companies
|
-
|
34.3
Composite
|
$12.02
|
Efficiency
100.0
|
|
Shell Companies
|
-
|
36.7
Composite
|
-
|
Efficiency
100.0
|
|
Shell Companies
|
-
|
36.7
Composite
|
$12.00
|
Efficiency
100.0
|
|
GBIO
Generation Bio Co.
Biotechnology
|
-
|
50.6
Composite
|
-
|
Efficiency
74.5
|
|
GNFT
GENFIT S.A.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
GOVXW
GeoVax Labs, Inc.
Biotechnology
|
-
|
39.6
Composite
|
-
|
Profitability
46.9
|
|
Shell Companies
|
-
|
60.2
Composite
|
$11.00
|
Profitability
65.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.50
|
No pillar score
-
|
|
Shell Companies
|
-
|
50.5
Composite
|
$0.00
|
Efficiency
66.7
|
|
Shell Companies
|
-
|
0.0
Composite
|
$10.82
|
No pillar score
-
|
|
Shell Companies
|
-
|
56.0
Composite
|
$11.00
|
Growth
94.2
|
|
Shell Companies
|
-
|
0.0
Composite
|
$6.56
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$6.50
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.04
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
GLYC
GlycoMimetics, Inc.
Biotechnology
|
-
|
43.5
Composite
|
-
|
Efficiency
61.1
|
|
Shell Companies
|
-
|
26.3
Composite
|
$10.72
|
Profitability
32.5
|
|
Shell Companies
|
-
|
37.7
Composite
|
$0.02
|
Profitability
50.3
|
|
Shell Companies
|
-
|
56.1
Composite
|
$10.87
|
Profitability
77.0
|
|
Shell Companies
|
-
|
56.1
Composite
|
$0.18
|
Profitability
77.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
HONDU
HCM II Acquisition Corp.
Shell Companies
|
-
|
35.7
Composite
|
-
|
Profitability
60.3
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$13.90
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
43.8
Composite
|
$10.80
|
Growth
100.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.18
|
No pillar score
-
|
|
Shell Companies
|
-
|
44.4
Composite
|
-
|
Profitability
61.7
|
|
HHGCU
HHG Capital Corporation
Shell Companies
|
-
|
44.4
Composite
|
-
|
Profitability
61.7
|
|
Shell Companies
|
-
|
45.2
Composite
|
-
|
Profitability
62.0
|
|
HLVX
HilleVax, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
46.8
Composite
|
$0.04
|
Profitability
61.7
|
|
Shell Companies
|
-
|
54.7
Composite
|
$9.02
|
Growth
100.0
|
|
Shell Companies
|
-
|
28.2
Composite
|
-
|
Profitability
53.9
|
|
Shell Companies
|
-
|
27.0
Composite
|
-
|
Profitability
48.4
|
|
HUMAW
Humacyte, Inc.
Biotechnology
|
-
|
46.4
Composite
|
$0.11
|
Efficiency
55.4
|
|
IMAB
I-MAB
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IKNA
Ikena Oncology, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IMTXW
Immatics N.V.
Biotechnology
|
-
|
49.6
Composite
|
-
|
Profitability
58.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
41.9
Composite
|
-
|
Profitability
56.0
|
|
Shell Companies
|
-
|
41.9
Composite
|
$2.31
|
Profitability
56.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
INZY
Inozyme Pharma, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
55.1
Composite
|
$11.49
|
Efficiency
69.0
|
|
Shell Companies
|
-
|
52.2
Composite
|
$10.40
|
Efficiency
69.0
|
|
Shell Companies
|
-
|
55.1
Composite
|
-
|
Efficiency
69.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.86
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.02
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$5.51
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
ISRLU
Israel Acquisitions Corp
Shell Companies
|
-
|
45.5
Composite
|
$11.02
|
Efficiency
66.3
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IXQWF
IX Acquisition Corp.
Shell Companies
|
-
|
29.8
Composite
|
-
|
Health
43.3
|
|
Biotechnology
|
-
|
45.3
Composite
|
$0.02
|
Health
64.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
JVSAU
JVSPAC Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
42.9
Composite
|
$11.50
|
Profitability
57.2
|
|
Shell Companies
|
-
|
42.9
Composite
|
$0.06
|
Profitability
57.2
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
45.5
Composite
|
$0.10
|
Growth
66.7
|
|
KRON
Kronos Bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
62.4
Composite
|
$0.63
|
Profitability
68.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
LEXXW
Lexaria Bioscience Corp.
Biotechnology
|
-
|
43.7
Composite
|
-
|
Health
48.6
|
|
Biotechnology
|
-
|
31.8
Composite
|
$0.02
|
Growth
66.7
|
|
Shell Companies
|
-
|
62.5
Composite
|
$30.28
|
Growth
73.9
|
|
Shell Companies
|
-
|
42.2
Composite
|
$36.05
|
Profitability
67.9
|
|
Shell Companies
|
-
|
42.2
Composite
|
-
|
Profitability
67.9
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
54.0
Composite
|
-
|
Profitability
69.2
|
|
MRUS
Merus N.V.
Biotechnology
|
-
|
45.5
Composite
|
-
|
Profitability
53.2
|
|
Shell Companies
|
-
|
22.5
Composite
|
-
|
Efficiency
36.9
|
|
Shell Companies
|
-
|
22.5
Composite
|
-
|
Efficiency
36.9
|
|
Shell Companies
|
-
|
30.4
Composite
|
-
|
Profitability
42.5
|
|
MTSR
Metsera, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
39.3
Composite
|
$0.03
|
Profitability
56.6
|
|
MCAA
Mountain
Shell Companies
|
-
|
42.9
Composite
|
-
|
Profitability
51.4
|
|
MCAAU
Mountain
Shell Companies
|
-
|
42.9
Composite
|
-
|
Profitability
51.4
|
|
Shell Companies
|
-
|
42.9
Composite
|
-
|
Profitability
51.4
|
|
Shell Companies
|
-
|
28.5
Composite
|
$10.92
|
Efficiency
66.7
|
|
MURA
Mural Oncology plc
Biotechnology
|
-
|
51.0
Composite
|
-
|
Profitability
55.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
43.7
Composite
|
-
|
Profitability
55.9
|
|
Shell Companies
|
-
|
43.7
Composite
|
-
|
Profitability
55.9
|
|
Biotechnology
|
-
|
31.2
Composite
|
$0.21
|
Profitability
38.5
|
|
Shell Companies
|
-
|
33.8
Composite
|
-
|
Efficiency
66.7
|
|
Shell Companies
|
-
|
33.8
Composite
|
-
|
Efficiency
66.7
|
|
Shell Companies
|
-
|
35.1
Composite
|
-
|
Efficiency
66.7
|
|
Biotechnology
|
-
|
50.5
Composite
|
$22.80
|
Health
57.0
|
|
Shell Companies
|
-
|
45.2
Composite
|
-
|
Profitability
50.2
|
|
Shell Companies
|
-
|
46.4
Composite
|
$12.99
|
Profitability
53.6
|
|
Shell Companies
|
-
|
67.8
Composite
|
$10.61
|
Growth
100.0
|
|
Biotechnology
|
-
|
42.0
Composite
|
-
|
Growth
43.5
|
|
NLSPW
NLS Pharmaceutics Ltd.
Biotechnology
|
-
|
0.0
Composite
|
$0.02
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
38.8
Composite
|
$0.01
|
Profitability
43.4
|
|
NTRBW
Nutriband Inc. Warrant
Biotechnology
|
-
|
35.5
Composite
|
$1.52
|
Profitability
45.0
|
|
Shell Companies
|
-
|
37.5
Composite
|
$12.07
|
Profitability
46.9
|
|
Shell Companies
|
-
|
61.0
Composite
|
$10.68
|
Growth
100.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
OABIW
OmniAb, Inc.
Biotechnology
|
-
|
53.6
Composite
|
$0.09
|
Profitability
65.5
|
|
Biotechnology
|
-
|
40.1
Composite
|
-
|
Efficiency
48.6
|
|
OPT
Opthea Limited
Biotechnology
|
-
|
29.7
Composite
|
-
|
Efficiency
43.2
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
42.3
Composite
|
$0.01
|
Profitability
54.7
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
37.9
Composite
|
-
|
Valuation
100.0
|
|
Shell Companies
|
-
|
3.4
Composite
|
-
|
Profitability
13.5
|
|
Shell Companies
|
-
|
28.8
Composite
|
-
|
Efficiency
54.1
|
|
Shell Companies
|
-
|
28.8
Composite
|
-
|
Efficiency
54.1
|
|
Shell Companies
|
-
|
28.8
Composite
|
-
|
Efficiency
54.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
66.9
Composite
|
$10.70
|
Growth
100.0
|
|
Shell Companies
|
-
|
36.2
Composite
|
-
|
Profitability
66.5
|
|
PRTG
Portage Biotech Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
42.9
Composite
|
-
|
Efficiency
63.7
|
|
Biotechnology
|
-
|
41.4
Composite
|
$0.02
|
Profitability
76.9
|
|
Shell Companies
|
-
|
39.2
Composite
|
-
|
Efficiency
100.0
|
|
Shell Companies
|
-
|
45.0
Composite
|
-
|
Efficiency
55.5
|
|
Shell Companies
|
-
|
37.9
Composite
|
-
|
Efficiency
72.2
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
45.8
Composite
|
$12.00
|
Efficiency
79.6
|
|
Shell Companies
|
-
|
60.0
Composite
|
$10.82
|
Growth
82.5
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
69.6
Composite
|
-
|
Profitability
87.6
|
|
Biotechnology
|
-
|
49.6
Composite
|
-
|
Profitability
67.4
|
|
Biotechnology
|
-
|
45.4
Composite
|
$0.01
|
Growth
68.9
|
|
Biotechnology
|
-
|
39.9
Composite
|
-
|
Efficiency
100.0
|
|
Biotechnology
|
-
|
40.8
Composite
|
$1.88
|
Efficiency
59.0
|
|
Shell Companies
|
-
|
58.7
Composite
|
$10.84
|
Profitability
83.6
|
|
RFACU
RF Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
RFAC
RF Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
33.5
Composite
|
$10.48
|
Growth
100.0
|
|
Shell Companies
|
-
|
50.7
Composite
|
$9.66
|
Growth
100.0
|
|
Biotechnology
|
-
|
56.5
Composite
|
$0.04
|
Growth
76.1
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
40.8
Composite
|
$0.03
|
Profitability
53.7
|
|
SIMAU
SIM Acquisition Corp I
Shell Companies
|
-
|
46.2
Composite
|
$10.89
|
Profitability
68.9
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
43.2
Composite
|
$11.32
|
Efficiency
66.7
|
|
Shell Companies
|
-
|
43.2
Composite
|
$0.22
|
Efficiency
66.7
|
|
Shell Companies
|
-
|
34.5
Composite
|
-
|
Profitability
42.3
|
|
Shell Companies
|
-
|
31.5
Composite
|
$12.70
|
Health
39.7
|
|
Shell Companies
|
-
|
32.0
Composite
|
-
|
Health
39.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
43.6
Composite
|
$10.55
|
Growth
100.0
|
|
SRZNW
Surrozen, Inc. Warrant
Biotechnology
|
-
|
34.4
Composite
|
$0.02
|
Health
38.4
|
|
Shell Companies
|
-
|
60.5
Composite
|
$10.60
|
Growth
100.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
$0.50
|
No pillar score
-
|
|
Biotechnology
|
-
|
53.1
Composite
|
$0.01
|
Profitability
59.5
|
|
Biotechnology
|
-
|
0.0
Composite
|
$3.39
|
No pillar score
-
|
|
Biotechnology
|
-
|
43.8
Composite
|
-
|
Health
58.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
TRML
Tourmaline Bio, Inc.
Biotechnology
|
-
|
41.8
Composite
|
-
|
Growth
57.3
|
|
Shell Companies
|
-
|
58.7
Composite
|
$10.44
|
Profitability
82.4
|
|
TRVN
Trevena, Inc.
Biotechnology
|
-
|
34.4
Composite
|
$0.01
|
Growth
47.4
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
VMCAW
Valuence Merger Corp. I
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
VMCAU
Valuence Merger Corp. I
Shell Companies
|
-
|
41.9
Composite
|
-
|
Profitability
71.4
|
|
VRNA
Verona Pharma plc
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
49.7
Composite
|
$11.21
|
Profitability
82.4
|
|
Biotechnology
|
-
|
37.1
Composite
|
-
|
Efficiency
61.1
|
|
Shell Companies
|
-
|
43.8
Composite
|
$12.80
|
Profitability
60.5
|
|
Shell Companies
|
-
|
28.6
Composite
|
-
|
Efficiency
46.0
|
|
Shell Companies
|
-
|
28.5
Composite
|
-
|
Efficiency
46.0
|
|
Shell Companies
|
-
|
56.7
Composite
|
$28.38
|
Profitability
84.5
|
|
Shell Companies
|
-
|
24.6
Composite
|
$11.32
|
Efficiency
47.9
|
|
Shell Companies
|
-
|
24.6
Composite
|
-
|
Efficiency
47.9
|
|
Biotechnology
|
-
|
64.5
Composite
|
$25.32
|
Profitability
80.0
|
|
Biotechnology
|
-
|
64.3
Composite
|
$25.24
|
Profitability
80.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
42.1
Composite
|
$11.10
|
Profitability
63.3
|
|
Shell Companies
|
-
|
27.8
Composite
|
$2.00
|
Profitability
49.3
|
|
Shell Companies
|
-
|
26.9
Composite
|
$10.02
|
Profitability
47.7
|
|
Shell Companies
|
-
|
26.9
Composite
|
-
|
Profitability
47.7
|
Try a broader company name, ticker, sector, or industry keyword.
This framework combines industry-specific diagnostics, moat context, and peer benchmarks so each signal stays grounded in how this business model actually compounds.
We group pre-commercial biotech and similarly early-stage businesses into a separate framework because revenue, margins, and near-term profitability are often the wrong lens. The money-flow engine starts with cash on hand, then follows operating expense, R&D intensity, operating cash burn, financing inflows, and estimated runway.
That same logic carries into the broader StatsAlpha(TM) framework. The trade-off ledger for pre-revenue biotech is intentionally sparse in the current implementation: profitability is disabled, safety focuses on liquidity and cash position, and the code explicitly flags the need for future runway and burn-specific calculators. That is a feature, not a gap in judgment. The framework avoids pretending these businesses can be compared like mature cash generators.
On the moat and valuation side, biotech currently inherits broader corporate tools where needed, but the fair-value defaults also acknowledge the category's binary nature and note that a probability-of-success layer would be preferable to a smooth-growth DCF. In practice, this profile should be read as a disciplined way to track funding durability and upside optionality, not as a shortcut to certainty. This framework is for informational purposes only, not investment advice.
Each layer answers a different question: where value is created, what protects it, and how execution compares with the rest of the coverage set.
Benchmarks and narrative cues are meant to clarify what the framework is seeing in the data. They are not investment advice.
Coverage starts with the companies that actually operate inside this business model, so peer comparisons stay relevant instead of generic.
The Biotech / Pre-Revenue layer isolates the cash-flow mechanics, capital demands, and operating risk that matter most for this industry.
We then layer in Corporate (default), pillar ranges, and peer leaders to show what strong execution looks like relative to the broader cohort.